

# CURRICULUM VITAE

## Jennifer Leigh Lund, PhD, MSPH

### PERSONAL

Name: Jennifer Leigh Lund  
Address: Department of Epidemiology  
McGavran-Greenberg Hall, Suite 2102-D  
University of North Carolina at Chapel Hill  
Chapel Hill, NC 27599-7435  
  
Phone: 919-966-7440 (office)  
Email: Jennifer.Lund@unc.edu

### EDUCATION

Doctor of Philosophy (Epidemiology) The University of North Carolina at Chapel Hill, Chapel Hill, NC	2009-2011
Master of Science in Public Health (Epidemiology) The University of North Carolina at Chapel Hill, Chapel Hill, NC	2007-2009
Bachelor of Arts (Quantitative Economics and International Relations) Tufts University, Medford, MA Summa cum laude	1999-2003

### PROFESSIONAL EXPERIENCE

Associate Professor, Department of Epidemiology Chapel Hill, NC	Fall 2019-
Director, Data Strategy and Education UNC Lineberger, Cancer Information and Public Health Resource Chapel Hill, NC	Fall 2019-
Assistant Professor, Department of Epidemiology Chapel Hill, NC	Fall 2013-2019
Visiting Scientist, Department of Clinical Epidemiology Aarhus University, Aarhus, Denmark	Fall 2013-2016

Post-Doctoral Researcher, Department of Clinical Epidemiology Aarhus University, Aarhus, Denmark	2012-2013
Consultant, New England Research Institute, Watertown, MA	2012-2013
Consultant, GlaxoSmithKline, Worldwide Epidemiology Research Triangle Park, NC	2012-2013
Graduate Research Assistant, GlaxoSmithKline, Worldwide Epidemiology Research Triangle Park, NC	2011-2012
Pre-doctoral Trainee, Digestive Disease Training Grant, School of Medicine Division of Gastroenterology and Hepatology The University of North Carolina at Chapel Hill	Fall 2008-2011
Graduate Research Assistant, GlaxoSmithKline, Worldwide Epidemiology Research Triangle Park, NC	Fall 2009
Graduate Research Assistant, School of Medicine, Division of Gastroenterology and Hepatology, Centro de Investigación de Demografía y Salud Leon, Nicaragua	Summer 2009
Graduate Research Assistant, School of Public Health Department of Health Policy and Management The University of North Carolina at Chapel Hill, NC	Fall 2008-2009
CRTA Fellow, National Cancer Institute, Applied Research Program Health Services and Economics Branch, Rockville, MD	Summer 2008
Graduate Research Assistant, School of Public Health Department of Health Policy and Management The University of North Carolina at Chapel Hill, NC	Spring 2008
Graduate Research Assistant, School of Public Health Department of Epidemiology The University of North Carolina at Chapel Hill, NC	Fall 2007
Senior Consultant, International Transfer Pricing Economics Ernst & Young LLP, New York, NY	2005-2007
Associate Analyst, National Economic Research Associates Healthcare Antitrust Practice, White Plains, NY	2003-2004

## HONORS

University of North Carolina at Chapel Hill, Thorp Faculty Engaged Scholars	July 2023-August 2025
---	-----------------------

International Society for Pharmacoepidemiology, Fellow Designation	April 2021
International Society for Geriatric Oncology, Young Investigator Award, Finalist Geneva, Switzerland	Nov 2019
Society for Epidemiologic Research Poster Award Third Best Poster (Top rating among >1500 posters) Baltimore, MD	June 2018
American Society for Preventive Oncology Annual Meeting Poster Contest Honorable Mention (Top four rating among >150 posters) New York, NY	March 2018
<i>Pharmacoepidemiology and Drug Safety</i> , Outstanding Reviewer	July 2017
Gordon H. DeFriese Career Development in Aging Research Award University of North Carolina at Chapel Hill, NC	December 2014
International Society for Pharmacoepidemiology Poster Walk, First Prize Comparative Effectiveness Research Special Interest Group Taipei, Taiwan	August 2014
American Society of Hematology, Abstract Achievement Award 55 <sup>th</sup> American Society of Hematology Annual Meeting New Orleans, LA	December 2013
Delta Omega Honor Society Member, Theta Chapter University of North Carolina at Chapel Hill	2012-present
Society for Epidemiologic Research, Student Dissertation Workshop Participant 3 <sup>rd</sup> Annual North American Congress of Epidemiology Montreal, Quebec, Canada	June 2011
Society for Epidemiologic Research, Student Travel Scholarship Award Recipient 3 <sup>rd</sup> Annual North American Congress of Epidemiology Montreal, Quebec, Canada	June 2011
International Society for Pharmacoepidemiology Scholarship Recipient 26 <sup>th</sup> Annual Meeting, Brighton, United Kingdom	August 2010
Methodologies in Healthcare Outcomes in Gastroenterology Trainee Scholarship Recipient, Gastroenterology Research Group (GRP) and the American Gastroenterological Association (AGA), Chicago, IL	September 2008
Audrey L. Hale Prize recipient, Tufts University, Medford, MA	May 2003

## MEMBERSHIPS

Council for International Organization of Medical Sciences (CIOMS) Working Group XV, Member The Role of Pharmacoepidemiology for Public Health	2023-present
Friends of Cancer Research Oncology Real-World Data Annual Roundtable The Current State of Oncology RWD: Overview of Select Collaborations, Discussant	Dec 2023
Reagan-Udall Foundation for the Food and Drug Administration Oncology Quality Characterization and Assessment of Real-World Data (QCARD) Initiative, Executive Committee Member	2022-2023
International Society of Geriatric Oncology Methods Working Group, Co-Chair	2015-present 2023-present
Cancer and Aging Research Group (CARG) Member NIA R21/R33 Health Services Research Core Co-Chair NIA R21/R33 Health Services Research Core Member	2015-present 2021-present 2020-2021
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center	2014-present
University of North Carolina at Chapel Hill, Center for Pharmacoepidemiology	2014-present
American Society of Clinical Oncology	2011-present
Society of Epidemiological Research (SER)	2009-present
International Society for Pharmacoepidemiology (ISPE) Co-Chair, Environmental Pharmacoepidemiology Special Interest Group Board of Directors Member Strategic Planning Committee Member	2009-present 2024-present 2021-2024 2022-2024

## BIBLIOGRAPHY

### BOOKS AND CHAPTERS

1. Raman SR, Landi SN, **Lund JL**, Jonsson Funk M. Chapter 11: Approaches to Mitigate Bias in the Design and Analysis of pRCTs. *Pragmatic Randomized Clinical Trials*. London: Academic Press; 2021; 131-147.
2. **Lund JL**, Yabroff KR. Chapter 23: Economic Burden of Cancer in the United States. *Cancer Rehabilitation and Survivorship: A Transdisciplinary Approach* Eds. Joanne Lester and Patricia Schmitt Oncology Nursing Society 2011; 239-46.

3. Tompa E, **Lund JL**, Yabroff KR. Chapter 15: Health Economics and Cancer Survivorship. *Health Services for Cancer Survivors: Practice, Policy and Research* Eds Michael Feuerstein and Patricia A Ganz. New York: Springer; 2011; 299-328

*REFEREED PAPERS: IN-PRESS AND PUBLISHED (N= 11,154 CITATIONS; H-INDEX=40)*

*\* First author is an undergraduate, graduate student, post-doc, or fellow for whom I was the primary mentor.*

1. Howlader N, **Lund JL**, Enewold L, Stevens J, McNeel T, Rivera D, Mariotto A, Cronin K. Real-World Lessons: Combining Cancer Registry and Retail Pharmacy Data for Oral Cancer Drugs. *Journal of the National Cancer Institute* (In-Press).
2. Latour CD, Delgado M, Su I, Wiener C, Acheampong CO, Poole C, Edwards JK, Quinto K, Stürmer T, **Lund JL**, Li J, Lopez N, Concato J, Jonsson Funk M. Use of Sensitivity Analyses to Assess Uncontrolled Confounding from Unmeasured Variables in Observational, Active Comparator Pharmacoepidemiologic Studies: A Systematic Review. *American Journal of Epidemiology* (In-Press).
3. Forster M, Deal AM, Page A, Vohra S, Wardell AC, Pak J, **Lund JL**, Nyrop KA, Muss HB. Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer. *Oncologist*. 2024 Jun 24:oyae150.
4. **Lund JL**, Matthews AA. Identifying target populations to align with decision makers' needs. *Am J Epidemiol*. E-pub ahead of print: June 19, 2024.
5. Thai ST, **Lund JL**, Poole C, Buse JB, Stürmer T, Harmon CA, Al-Obaidi M, Williams GR. Skeletal muscle density performance for screening frailty in older adults with cancer and the impact of diabetes: The CARE Registry. *J Geriatr Oncol*. 2024 Jun 18;15(6):101815.
6. Richardson DR, Zhou X, Reeder-Hayes K, Jensen CE, Islam J, Loh KP, Gupta A, Basch E, Bennett AV, Bridges JFP, Wheeler SB, Wood WA, Baggett CD, **Lund JL**. Home Time Among Older Adults With Acute Myeloid Leukemia Following Chemotherapy. *JAMA Oncol*. 2024 Jun 13:e241823.
7. Metwally EM, **Lund JL**, Drummond MB, Peacock Hinton S, Poole C, Thompson CA. COPD With Lung Cancer Among Older United States Adults: Prevalence, Diagnostic Timeliness, and Association With Earlier Stage Tumors. *Chronic Obstr Pulm Dis*. E-pub ahead of print: June 5, 2024.
8. Niznik JD, **Lund JL**, Hanson LC, Colón-Emeric C, Kelley CJ, Gilliam M, Thorpe CT. A comparison of dementia diagnoses and cognitive function measures in Medicare claims and the Minimum Data Set. *J Am Geriatr Soc*. E-pub ahead of print: May 30, 2024.
9. Gaber CE, Hanson K, Kim S, **Lund JL**, Lee T, Murray EJ. The clone-censor-weight method in pharmacoepidemiologic research: foundations and methodological implementation. *Current Epidemiology Reports* (In-Press).

10. Liu F, Duchesneau ED, **Lund JL**, Jackson J. A Review of Causal Inference Methods for Estimating the Effects of Exposure Change When Incident Exposure Is Unobservable. *Current Epidemiology Reports* (In-Press).
11. Ehrenstein V, Poulsen MH, Kahlert J, Langan SM, Urushihara H, Marinac-Dabic D, **Lund JL**, Sørensen HT, Benchimol EI. Validation of algorithms in studies based on routinely collected health data: general principles. *American Journal of Epidemiology*. E-pub ahead of print: May 17, 2024.
12. \* Duchesneau ED, Reeder-Hayes K, Stürmer T, Kim DH, Edwards JK, **Lund JL**. Longitudinal trajectories of a claims-based frailty measure during adjuvant chemotherapy in women with stage I-III breast cancer. *Oncologist*. (E-pub ahead of print: May 8, 2024).
13. \* Duchesneau ED, Stürmer T, Kim DH, Reeder-Hayes K, Edwards JK, Faurot KR, **Lund JL**. Performance of a Claims-Based Frailty Proxy Using Varying Frailty Ascertainment Lookback Windows. *Med Care*. 2024 May 1;62(5):305-313.
14. Henderson LM, Su IH, Rivera MP, Pak J, Chen X, Reuland DS, **Lund JL**. Prevalence of Lung Cancer Screening in the US, 2022. *JAMA Netw Open*. 2024 Mar 4;7(3):e243190.
15. **Lund JL**, Cacciatore J, Tylock R, Su IH, Sharma S, Hinton SP, Smith S, Nowels MA, Chen X, Duberstein PR, Hanson LC, Mohile SG. Development and Evaluation of a Multisource Approach to Extend Mortality Follow-Up for Older Adults With Advanced Cancer Enrolled in Randomized Trials. *JCO Clin Cancer Inform*. 2024 Apr;8:e2300183.
16. Niznik JD, Shmuel S, Pate V, Thorpe CT, Hanson LC, Rice C, **Lund JL**. Validating claims-based definitions for deprescribing: Bridging the gap between clinical and administrative data. *Pharmacoepidemiol Drug Saf*. 2024 Apr;33(4):e5784.
17. Gaber CE, Abdelaziz AI, Sarker J, **Lund JL**, Dellon ES, Cotton CC, Eluri S, Shaheen NJ. Adherence to prescription proton pump inhibitor therapy amongst individuals diagnosed with Barrett's esophagus. *Pharmacoepidemiol Drug Saf*. 2024 Feb;33(2):e5760.
18. Kirkegård J, Gaber C, Heide-Jørgensen U, Fristrup CW, **Lund JL**, Cronin-Fenton D, Mortensen FV. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. *J Natl Cancer Inst*. (E-pub ahead of print: February 4, 2024).
19. \* Jensen CE, Kuo TM, LeBlanc MR, Baggett CD, Duchesneau ED, Zhou X, Reeder-Hayes KE, **Lund JL**. Functional Status Associations With Treatment Receipt and Outcomes Among Older Adults Newly Diagnosed With Multiple Myeloma. *JCO Clin Cancer Inform*. 2024 Feb;8:e2300214.
20. \* Pak J, Nyrop KA, Muss HB, Forster MK, **Lund JL**. Quantifying Chemotherapy Delivery in Older and Younger Women With Early-Stage Breast Cancer Using Longitudinal Cumulative Dose. *Oncologist*. 2024 Apr 4;29(4):311-315.
21. \* Thai ST, **Lund JL**, Kenzik KM, Poole C, Stürmer T, Buse JB, Harmon CA, Al-Obaidi M, Williams GR. Geriatric Assessment Impairment Profiles and Mortality in Older Adults with

- Gastrointestinal Cancers: Latent Class Analysis of the CARE Registry. *J Gerontol A Biol Sci Med Sci.* (E-pub ahead of print: Dec 10, 2023).
22. Niznik JD, Kelley CJ, Fasth L, Colón-Emeric C, Thorpe CT, Gilliam MA, **Lund JL**, Hanson LC. Deprescribing bisphosphonates for older adults with dementia: perspectives of caregivers. *Osteoporos Int.* 2023 Nov 18.
  23. \* Duchesneau ED, Shmuel S, Faurot KR, Park J, Musty A, Pate V, Kinlaw AC, Stürmer T, Yang YC, Funk MJ, **Lund JL**. Translation of a claims-based frailty index from International Classification of Diseases 9th Revision to 10th Revision. *Am J Epidemiol* (E-pub ahead of print: July 11, 2023)
  24. Niznik J, Colón-Emeric C, Thorpe CT, Kelley CJ, Gilliam M, **Lund JL**, Hanson LC. Prescriber Perspectives and Experiences with Deprescribing Versus Continuing Bisphosphonates in Older Nursing Home Residents with Dementia. *J Gen Intern Med* (E-pub ahead of print: June 27, 2023).
  25. **Lund JL**, Webster-Clark MA, Westreich D, Sanoff HK, Robert N, Frytak JR, Boyd M, Shmuel S, Stürmer T, Keil AP. Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice. *Epidemiology.* 2024 Mar 1;35(2):241-251.
  26. Olsson LT, Hamilton AM, Van Alsten SC, **Lund JL**, Stürmer T, Nichols HB, Reeder-Hayes KE, Troester MA. Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer. *Breast Cancer Res Treat.* 2024 Feb;204(1):107-116.
  27. Mohamed MR, Rich DQ, Seplaki C, **Lund JL**, Flannery M, Culakova E, Magnuson A, Wells M, Tylock R, Mohile SG. Primary Treatment Modification and Treatment Tolerability Among Older Chemotherapy Recipients With Advanced Cancer. *JAMA Netw Open.* 2024 Feb 5;7(2):e2356106.
  28. \* Musty A, **Lund JL**, Yang YC, Niznik J, Shmuel S, Duchesneau ED. The association between wealth and sleep medication use in a nationally-representative sample of older Medicare beneficiaries. *Pharmacoepidemiol Drug Saf.* 2024 Jan;33(1):e5703.
  29. \* Duchesneau ED, McNeill AM, Schary W, Pate V, **Lund JL**. Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study. *J Geriatr Oncol.* 2023 Nov;14(8):101602.
  30. Anderson C, Peery AF, Bae-Jump VL, Brewster WR, **Lund JL**, Olshan AF, Nichols HB. Gastrointestinal outcomes among older women with endometrial cancer. *Gynecol Oncol.* 22;175:114-120.
  31. \* Duchesneau ED, Shmuel S, Faurot KR, Musty A, Park J, Stürmer T, Kinlaw AC, Yang YC, **Lund JL**. Missing data approaches in longitudinal studies of aging: A case example using the National Health and Aging Trends Study. *PLoS One.* 2023 Jun 8;18(6):e0286984.
  32. \* Hsu CD, Henderson LM, Jackson BE, Baggett CD, Funk MJ, Olshan AF, Gupta P, Barritt AS, Sanoff HK, Wheeler SB, Moon AM, **Lund JL**. Hepatocellular Carcinoma Surveillance Among Individuals with Cirrhosis: Trends by Payer, Etiology and Calendar Year, from a Statewide,

Multi-Payer Dataset, 2010-2018. *Cancer Epidemiology, Biomarkers and Prevention* (E-pub ahead of print: May 10, 2023).

33. \* Lee S, Bennett AV, Zhou X, Warner AB, Trogdon JG, Kent EE, **Lund JL**. Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy. *Pharmacoepidemiology and Drug Safety* (E-pub ahead of print: April 24, 2023).
34. \* Yang JY, **Lund JL**, Funk MJ, Hudgens MG, Lewis JD, Kappelman MD. Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). *Am J Gastroenterol*. (E-pub ahead of print: April 13, 2023). PMID: 37053548.
35. \* Gaber CE, Edwards JK, **Lund JL**, Peery AF, Richardson DB, Kinlaw AC. Inverse probability weighting to estimate exposure effects on the burden of recurrent outcomes in the presence of competing events. *Am J Epidemiol* (E-pub ahead of print: February 14, 2023).
36. Fix J, Vielot NA, **Lund JL**, Weber DJ, Smith JS, Hudgens MG, Becker-Dreps S. Patterns of use of recombinant zoster vaccine among commercially insured immunocompetent and immunocompromised adults 50-64 years old in the United States. *Vaccine* (E-pub ahead of print: November 14, 2022).
37. \* D'Arcy ME, Stürmer T, Sandler RS, Baron JA, Jonsson-Funk ML, Troester MA, **Lund JL**. Healthcare system engagement and algorithm-identified cancer incidence following initiation of a new medication. *Pharmacoepidemiol Drug Saf*. (E-pub ahead of print: November 17, 2022).
38. Niznik J, Gilliam M, Colón-Emeric C, Thorpe CT, **Lund JL**, Berry S, Hanson LC. Controversies in Osteoporosis Treatment of Nursing Home Residents. *J Am Med Dir Assoc*. (E-pub ahead of print: November 3, 2022).
39. \* Shmuel S, Leonard CE, Bykov K, Filion KB, Seamans MJ, **Lund JL**. Breaking Research Silos and Stimulating "Innovation at the Edges" in Epidemiology. *Am J Epidemiol*. (E-pub ahead of print: Nov 3, 2022).
40. \* Gaber CE, Shaheen NJ, Edwards JK, Sandler RS, Nichols HB, Sanoff HK, **Lund JL**. Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer. *JNCI Cancer Spectr*. 2022 Nov 1;6(6):pkac069.
41. Park J, **Lund JL**, Kent EE, Anderson C, Brewster WR, Olshan AF, Nichols HB. Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer. *J Geriatr Oncol*. (E-pub ahead of print: September 7, 2022).
42. \* Duchesneau ED, Jackson BE, Webster-Clark M, **Lund JL**, Reeder-Hayes KE, Nápoles AM, Strassle PD. The timing, the treatment, the question: Comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example. *Cancer Epidemiol Biomarkers Prev*. 2022 Aug 19:EPI-22-0495.

43. \* Pak J, **Lund JL**, Keil A, Westreich D, Stürmer T, Wohl D, Farel C, Drummond MB, Webster-Clark M. A Systematic Review of Whether COVID-19 Randomized Controlled Trials Reported on Demographic and Clinical Characteristics. *Pharmacoepidemiology and Drug Safety* (E-pub ahead of print: August 22, 2022).
44. \* Gaber CE, Shaheen NJ, Sandler RS, Edwards JK, Nichols HB, Sanoff HK, **Lund JL**. Patterns of care amongst older adults diagnosed with locally advanced esophageal cancer: A cohort study. *J Geriatr Oncol*. 2022 Nov;13(8):1178-1187.
45. \* Webster-Clark M, Keil AP, Robert N, Frytak JR, Boyd M, Stürmer T, Sanoff H, Westreich D, **Lund JL**. Comparing Trial and Real-world Adjuvant Oxaliplatin Delivery in Patients With Stage III Colon Cancer Using a Longitudinal Cumulative Dose. *JAMA Oncol*. 2022 Oct 13;8(12):1821–4.
46. Anderson C, Olshan AF, Bae-Jump VL, Brewster WR, **Lund JL**, Nichols HB. Cardiovascular disease diagnoses among older women with endometrial cancer. *Gynecol Oncol*. 2022 Oct;167(1):51-57.
47. \* Yang JY, **Lund JL**, Pate V, Kappelman MD. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. *Inflammatory Bowel Diseases* (E-pub ahead of print: August 5, 2022).
48. Anderson C, Olshan AF, Park J, Bae-Jump V, Brewster W, **Lund JL**, Nichols HB. Adverse urinary system outcomes among older women with endometrial cancer. *Cancer Epidemiology, Biomarkers and Prevention* (E-pub ahead of print: May 11, 2022).
49. Benbow JH, Rivera DR, **Lund JL**, Feldman JE, Kim ES. Increasing Inclusiveness of Patient-Centric Clinical Evidence Generation in Oncology: Real-World Data and Clinical Trials. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-11.
50. Loh KP, Seplaki CL, Sanapala C, Yousefi-Nooraie R, **Lund JL**, Epstein RM, Duberstein PR, Flannery M, Culakova E, Xu H, McHugh C, Klepin HD, Lin PJ, Watson E, Grossman VA, Liu JJ, Geer J, O'Rourke MA, Mustian K, Mohile SG. Association of Prognostic Understanding With Health Care Use Among Older Adults With Advanced Cancer: A Secondary Analysis of a Cluster Randomized Clinical Trial. *JAMA Netw Open*. 2022 Feb 1;5(2):e220018.
51. Sarri G, Bennett D, Debray T, Deruaz-Luyet A, Soriano Gabarró M, Largent JA, Li X, Liu W, **Lund JL**, Moga DC, Gokhale M, Rentsch CT, Wen X, Yanover C, Ye Y, Yun H, Zullo AR, Lin KJ. ISPE-endorsed guidance in using electronic health records for comparative effectiveness research in COVID-19: opportunities and trade-offs. *Clin Pharmacol Ther*. (E-pub ahead of print: February 16, 2022).
52. \* Duchesneau ED, Kinlaw AC, Jonsson Funk M, Pate V, **Lund JL**. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019. *Pharmacoepidemiology and Drug Safety* (E-pub ahead of print: January 27, 2022).

53. \* Chun DS, Hicks B, Hinton SP, Funk MJ, Gooden K, Keil AP, Tan HJ, Stürmer T, **Lund JL**. Comparison of Approaches for Measuring Adherence and Persistence to Oral Oncologic Therapies in Patients Diagnosed with Metastatic Renal Cell Carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2022 Apr 1;31(4):893-899.
54. \* Gaber CE, Cotton CC, Eluri S, **Lund JL**, Farrell TM, Dellon ES. Autoimmune and viral risk factors are associated with achalasia: A case-control study. *Neurogastroenterol Motil.* 2021 Dec 26:e14312.
55. Penberthy LT, Rivera D, **Lund JL**, Bruno M, Meyer AM. An Overview of Real-World Data Sources for Oncology and Considerations for Research. *CA: A Cancer Journal for Clinicians* (E-pub ahead of print: December 29, 2021).
56. Trogdon JG, Amin K, Gupta P, Urick BY, Reeder-Hayes KE, Farley JF, Wheeler SB, Spees L, **Lund JL**. Providers' mediating role for medication adherence among cancer survivors. *PLoS One.* 2021 Nov 29;16(11):e0260358.
57. Hicks BM, Chun DS, Peacock Hinton S, Hsu CD, Tan HJ, **Lund JL**. Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma. *J Geriatr Oncol.* 2021 Nov 12:S1879-4068(21)00252-6.
58. Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, **Lund JL**, Moon AM, Pate V, Barnes EL, Schlusser CL, Baron TH, Shaheen NJ, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. *Gastroenterology.* 2021 Oct 19:S0016-5085(21)03655-6.
59. **Lund JL**, Duberstein PR, Loh KP, Gilmore N, Plumb S, Lei L, Keil AP, Islam JY, Hanson LC, Giguere JK, Vogel VG, Burnette BL, Mohile SG. Life expectancy in older adults with advanced cancer: Evaluation of a geriatric assessment-based prognostic model. *J Geriatr Oncol.* 2021 Sep 2:S1879-4068(21)00197-1.
60. \* Shmuel S, Pate V, Pepin MJ, Bailey JC, Golightly YM, Hanson LC, Stürmer T, Naumann RB, Gnjidic D, **Lund JL**. Effects of anticholinergic and sedative medication use on fractures: A self-controlled design study. *J Am Geriatr Soc.* 2021 Nov;69(11):3212-3224.
61. Tjia J, **Lund JL**, Mack DS, Mbrah A, Yuan Y, Chen Q, Osundolire S, McDermott CL. Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life. *Current Epidemiology Reports.* 2021(8): 116–129.
62. Herb JN, Wolff R, McDaniel P, **Lund JL**, Holmes M, Stitzenberg KB. “Rural Representation of the Surveillance, Epidemiology, and End Results Database” *Cancer Causes and Control* (In-Press).
63. \* Hsu CD, Nichols HB, **Lund JL**. Polypharmacy and medication use by cancer history in a nationally representative group of adults in the USA, 2003-2014. *J Cancer Surviv.* 2022 Jun;16(3):659-666.

64. \* Gaber CE, Eluri S, Cotton CC, Strassle PD, Farrell TM, **Lund JL**, Dellon ES. Epidemiologic and Economic Burden of Achalasia in the United States. *Clin Gastroenterol Hepatol*. 2022 Feb;20(2):342-352.e5.
65. \* Gaber CE, Kinlaw AC, Edwards JK, **Lund JL**, Stürmer T, Peacock Hinton S, Pate V, Bartelt LA, Sandler RS, Peery AF. Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis : Two Nationwide Cohort Studies. *Ann Intern Med*. 2021 Jun;174(6):737-746.
66. Stürmer T, Webster-Clark M, **Lund JL**, Wyss R, Ellis AR, Lunt M, Rothman KJ, Glynn RJ. Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study. *Am J Epidemiol*. 2021 Aug 1;190(8):1659-1670
67. \* Webster-Clark MA, Keil AP, Sanoff HK, Sturmer T, Westreich D, **Lund JL**. Introducing Longitudinal Cumulative Dose to Describe Chemotherapy Patterns Over Time: Case Study of a Colon Cancer Trial. *International Journal of Cancer*. 2021 Jul 15;149(2):394-402.
68. Jackson BE, Greenup RA, Strassle PD, Deal AM, Baggett CD, **Lund JL**, Reeder-Hayes KE. Understanding and identifying immortal-time bias in surgical health services research: An example using surgical resection of stage IV breast cancer. *Surg Oncol*. 2021 Mar 5;37:101539.
69. Gartner DR, Delamater PL, Hummer RA, **Lund JL**, Pence BW, Robinson WR. Patterns of black and white hysterectomy incidence among reproductive aged women. *Health Serv Res*. 2021 Feb 21.
70. Reeder-Hayes KE, Mayer SE, **Lund JL**. Adherence to Endocrine Therapy Including Ovarian Suppression: A Large Observational Cohort Study of US Women with Early Breast Cancer. *Cancer*. 2021 Apr 15;127(8):1220-1227.
71. Moon AM, Sanoff HK, Chang Y, **Lund JL**, Barritt AS, Hayashi PH, Stitzenberg KB. Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival. *J Natl Compr Canc Netw*. 2021 Feb 12:1-9.
72. Tan HJ, Zhou X, Spratte BN, McMahon S, Nielsen ME, **Lund JL**, Harris AHS, Smith AB, Basch E. Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. *J Urol*. 2021 Feb;205(2):434-440.
73. Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Bhaskaran K, **Lund JL** (co-senior authors). Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study. *J Natl Compr Canc Netw* (E-pub ahead of print: January 5, 2021).
74. Matthews AA, Hinton SP, Stanway S, Lyon AR, Smeeth L, **Lund JL**, Bhaskaran K (co-senior authors). Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. *Heart*. 2021 Aug;107(16):1327-1335.
75. **Lund JL**, Webster-Clark MA, Hinton SP, Shmuel S, Stürmer T, Sanoff HK. Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach. *Pharmacoepidemiol Drug Saf*. 2020 Dec;29(12):1579-1587.

76. \* Shmuel S, Pate V, Pepin MJ, Bailey JC, Hanson LC, Stürmer T, Naumann RB, Golightly YM, Gnjjidic D, **Lund JL**. Quantifying Cumulative Anticholinergic and Sedative Drug Load Among US Medicare Beneficiaries. *Pharmacoepidemiol Drug Saf*. 2021 Feb;30(2):144-156.
77. Suarez EA, Boggess K, Engel SM, Stürmer T, **Lund JL**, Funk MJ. Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. *Pharmacoepidemiol Drug Saf*. 2021 Feb;30(2):114-125.
78. Suarez EA, Boggess K, Engel SM, Stürmer T, **Lund JL**, Jonsson Funk M. Ondansetron use in early pregnancy and the risk of miscarriage. *Pharmacoepidemiol Drug Saf*. 2021 Feb;30(2):103-113.
79. \* Webster-Clark M, Ross RK, **Lund JL**. Initiator Types and the Causal Question of the Prevalent New-User Design: A Simulation Study. *Am J Epidemiol*. 2021 Jul 1;190(7):1341-1348.
80. Billock RM, Mucha PJ, Samoff E, Dennis AM, Pence BW, **Lund JL**, Powers KA. Network Interconnectivity and Community Detection in the HIV/Syphilis Syndemic among Men who have Sex with Men. *Sexually Transmitted Diseases*. 2020 Nov;47(11):726-732.
81. \* Ross RK, Kuo TM, Webster-Clark M, Lewis CL, Kistler CE, Jonsson Funk M, **Lund JL**. Validation of a 5-Year Mortality Prediction Model among U.S. Medicare Beneficiaries. *J Am Geriatr Soc*. 2020 Dec;68(12):2898-2902.
82. \* Webster-Clark M, **Lund JL**, Stürmer T, Poole C, Simpson RJ, Edwards JK. Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation. *Epidemiology*. 2020 Sep;31(5):605-613.
83. Engeda JC, Lhachimi SK, Rosamond WD, **Lund JL**, Keyserling TC, Safford MM, Colantonio LD, Muntner P, Avery CL. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study. *PLoS Med*. 2020 Aug 26;17(8):e1003280.
84. Spees LP, Wheeler SB, Zhou X, Amin KB, Baggett CD, **Lund JL**, Urick BY, Farley JF, Reeder-Hayes KE, Trogon JG. Changes in chronic medication adherence, costs, and health care use after a cancer diagnosis among low-income patients and the role of patient-centered medical homes. *Cancer*. 2020 Nov 1;126(21):4770-4779.
85. \* Webster-Clark M, Stürmer T, Edwards JK, Poole C, Simpson RJ Jr, **Lund JL**. Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. *Pharmacoepidemiol Drug Saf*. 2020 Aug;29(8):832-841.
86. \* Carty RW, Langworthy BW, Fine JP, Buse JB, Sanoff HK, **Lund JL**. Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. *Oncologist*. 2020 Jul;25(7):579-584.

87. \* Chun DS, Faso A, Muss HB, Sanoff HK, Valgus J, **Lund JL**. Oncology pharmacist-led medication reconciliation among cancer patients initiating chemotherapy. *J Oncol Pharm Pract*. 2020 Jul;26(5):1156-1163.
88. **Lund JL**, Gupta P, Amin KB, Meng K, Urick BY, Reeder-Hayes KE, Farley JF, Wheeler SB, Spees L, Trogdon JG. Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts. *J Geriatr Oncol*. 2021 Jan;12(1):72-79.
89. Gartner DR, Delamater PL, Hummer RA, **Lund JL**, Pence BW, Robinson WR. Integrating Surveillance Data to Estimate Race/Ethnicity-specific Hysterectomy Inequalities Among Reproductive-aged Women: Who's at Risk? *Epidemiology*. 2020 May;31(3):385-392.
90. Cole AL, Wood WA Jr, Mulunch B, **Lund JL**, Elston Lafata J, Dusetzina SB. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. *JCO Oncol Pract*. 2020 May;16(5):e443-e455.
91. BrintzenhofeSzoc K, Krok-Schoen JL, Canin B, Parker I, MacKenzie AR, Koll T, Vankina R, Hsu CD, Jang B, Pan K, **Lund JL**, Starbuck E, Shahrokni A. The underreporting of phase III chemotherapeutic clinical trial data of older patients with cancer: A systematic review. *J Geriatr Oncol*. 2020 Apr;11(3):369-379.
92. Wong ML, Lichtman SM, Morrow GR, Simmons J, Hargraves T, Gross CP, **Lund JL**, Lowenstein LM, Walter LC, McDermott CL, Mohile SG, Cohen HJ. Geriatric oncology health services research: Cancer and Aging Research Group Infrastructure Core. *J Geriatr Oncol*. 2020 Mar;11(2):350-354.
93. Kirkegård J, Gaber C, **Lund JL**, Hinton SP, Ladekarl M, Heide-Jørgensen U, Cronin-Fenton D, Mortensen FV. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. *Cancer Epidemiol*. 2020 Feb;64:101647.
94. \* Hsu CD, Hinton SP, Reeder-Hayes KE, Sanoff HK, **Lund JL**. Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide. *Cancer Epidemiol Biomarkers Prev*. 2020 Feb;29(2):520-523.
95. Kirkegård J, **Lund JL**, Mortensen FV, Cronin-Fenton D. Statins and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis: A Danish nationwide population-based cohort study. *International Journal of Cancer*. 2020 Feb 1;146(3):610-616.
96. \* Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, **Lund JL**. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. *Oncologist*. 2020 Jan;25(1):46-54.
97. Rivera DR, Gokhale MN, Reynolds MW, Andrews EB, Chun D, Haynes K, Jonsson-Funk ML, Lynch KE, **Lund JL**, Strongman H, Bhullar H, Raman SR. Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility. *Pharmacoepidemiol Drug Saf*. 2020 Jan;29(1):18-29.

98. Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, Stürmer T, **Lund JL**. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. *Pharmacoepidemiol Drug Saf*. 2020 Jan;29(1):9-17.
99. Stürmer T, Wang T, Golightly YM, Keil A, **Lund JL**, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. *Rheumatology (Oxford)*. 2020 Jan 1;59(1):14-25.
100. Strassle PD, Sickbert-Bennett EE, Klompas M, **Lund JL**, Stewart PW, Marx AH, DiBiase LM, Weber DJ. Incidence and risk factors of non-device-associated pneumonia in an acute-care hospital. *Infect Control Hosp Epidemiol*. 2020 Jan;41(1):73-79.
101. \* Shmuel S, **Lund JL**, Alvarez C, Hsu CD, Palta P, Kucharska-Newton A, Jordan JM, Nelson AE, Golightly YM. Polypharmacy and Incident Frailty in a Longitudinal Community-based Cohort Study. *Journal of the American Geriatrics Society* 2019 Dec;67(12):2482-2489.
102. \* Htoo P, Stürmer T, Funk MJ, Pate V, Simpson RJ, **Lund JL**. Renin-Angiotensin-Aldosterone System-Based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries. *Epidemiology*. 2019 Nov;30(6):867-875.
103. Strassle PD, Sickbert-Bennett EE, Klompas M, **Lund JL**, Stewart PW, Marx AH, DiBiase LM, Weber DJ. Incidence and risk factors of non-device-associated urinary tract infections in an acute-care hospital. *Infect Control Hosp Epidemiol*. 2019 Nov;40(11):1242-1247.
104. Anderson C, **Lund JL**, Weaver MA, Wood WA, Olshan AF, Nichols HB. Disparities in mortality from noncancer causes among adolescents and young adults with cancer. *Cancer Epidemiology, Biomarkers, and Prevention*. 2019 Sep;28(9):1417-1426.
105. Kehoe LA, Xu H, Duberstein P, Loh KP, Culakova E, Canin B, Hurria A, Dale W, Wells M, Gilmore N, Kleckner AS, **Lund J**, Kamen C, Flannery M, Hoerger M, Hopkins JO, Liu JJ, Geer J, Epstein R, Mohile SG. Quality of Life of Caregivers of Older Patients with Advanced Cancer. *J Am Geriatr Soc*. 2019 May;67(5):969-977.
106. Garry EM, Buse JB, Gokhale M, **Lund JL**, Nielson ME, Pate V, Stürmer T. Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes. *Diabetes, Obesity, and Metabolism*. 2019 Sep;21(9):2096-2106.
107. \* Yang JY, Webster-Clark M, **Lund JL**, Sandler RS, Dellon ES, Stürmer T. Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. *Gastrointestinal Endoscopy*. 2019 Sep;90(3):360-369.
108. Zhang HT, McGrath LJ, Ellis AR, Wyss R, **Lund JL**, Stürmer T. Restriction of Pharmacoepidemiologic Cohorts to Initiators of Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults. *American Journal of Epidemiology*. 2019 Jul 1;188(7):1371-1382.

109. Loh KP, Mohile SG, **Lund JL**, Epstein R, MD, Lei L, Culakova E, McHugh C, Wells M, Gilmore N, Mohamed MR, Kamen C, Aarne V Conlin A, Bearden J, Onitilo A, Wittink M, Dale W, Hurria A, Duberstein P. Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists. *The Oncologist*. 2019 Jun;24(6):e292-e302.
110. Lycke KD, Christiansen CF, **Lund JL**, Iversen LH, Nørgaard M. Preadmission use of antidepressants and risk of complications and death after colorectal cancer surgery: A nationwide population-based cohort study. *Colorectal Diseases* 2019 Jun;21(6):651-662.
111. Anderson C, **Lund JL**, Weaver MA, Wood WA, Olshan AF, Nichols HB. Noncancer mortality among adolescents and young adults with cancer. *Cancer* 2019 Jun 15;125(12):2107-2114.
112. **Lund JL**, Kuo M, Brookhart MA, Meyer AM, Dalton AF, Kistler CE, Wheeler SB, Lewis CL. Development and validation of a five-year mortality prediction model using machine learning and Medicare data. *Pharmacoepidemiology and Drug Safety* 2019 May;28(5):584-592.
113. Mitchell AP, Winn AN, **Lund JL**, Dusetzina SB. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. *The Oncologist* 2019 May;24(5):632-639.
114. Williams GR, Dunham L, Chang YK, Deal AM, Pergolotti M, **Lund JL**, Guerard E, Kenzik K, Muss HB, and Sanoff HK. Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Utilization in Older Adult Cancer Survivors. *Journal of Oncology Practice* 2019 May;15(5):e399-e409.
115. Engeda JC, Stackhouse A, White M, Rosamond WD, Lhachimi SK, **Lund JL**, Keyserling TC, Avery CL. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. *Diabetes Research and Clinical Practice* 2019 May;151:96-105.
116. \* Yang JY, Peery AF, **Lund JL**, Pate V, Sandler RS. Burden and Cost of Outpatient Hemorrhoids in the United States Employer-Insured Population, 2014. *American Journal of Gastroenterology* 2019 May;114(5):798-803.
117. \* Hester LL, Park SI, Wood WA, Stürmer T, Brookhart MA, **Lund JL**. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes in the rituximab era. *Cancer* 2019 Apr 1;125(7):1101-1112.
118. \* Mayer SE, Tan HJ, Hinton SP, Sanoff HK, Stürmer T, Hester LL, Faurot KR, Funk MJ, **Lund JL**. Comparison of Medicare claims-based measures of poor physical function and associations with treatment receipt and mortality in older colon cancer patients. *Medical Care* 2019 Apr;57(4):286-294.
119. Van Rompay MI, Nickel JC, Ranganathan G, Kantoff PW, Solomon KR, **Lund JL**, McKinlay JB. Impact of 5 $\alpha$ -Reductase Inhibitors and  $\alpha$ -Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality. *British Journal of Urology International* 2019 Mar;123(3):511-518.

120. Nishijima TF, Deal AM, **Lund JL**, Nyrop KA, Muss HB, Sanoff HK. Inflammatory markers and overall survival in older adults with cancer. *Journal of Geriatric Oncology* 2019 Mar;10(2):279-284.
121. \* Chun D, **Lund JL**, Til Stürmer. Pharmacoepidemiology and Drug Safety's special issue on validation studies. *Pharmacoepidemiology and Drug Safety* 2019 Feb;28(2):123-125.
122. AF Peery, Crockett SD, Murphy CC, **Lund JL**, Dellon ED, Williams JL, Jensen ET, NJ Shaheen, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Baron TH, Galanko J, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. *Gastroenterology* 2019 Jan;156(1):254-272.
123. Barry EL, **Lund JL**, Westreich D, Mott LA, Ahnen DJ, Beck GJ, Bostick RM, Bresalier RS, Burke CA, Church TR, Rees JR, Robertson DJ, Baron JA. Body Mass Index, Calcium Supplementation and Risk of Colorectal Adenomas. *International Journal of Cancer* 2019 Feb 1;144(3):448-458.
124. \* Webster-Clark MA, Sanoff HK, Stürmer T, Hinton SP, **Lund JL**. Diagnostic assessment of transportability of intervention effects from a randomized trial to a routine care population: An application to metastatic colorectal cancer. *Epidemiology* 2019 Jan;30(1):103-111.
125. Young JC, **Lund JL**, Dasgupta N, Jonsson Funk M. Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids. *Pharmacoepidemiology and Drug Safety* 2019 Jan;28(1):39-47.
126. Naumann RB, Marshall SW, Gottfredson NC, **Lund JL**, Ringwalt CL, Skinner AC. Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance "lock-in" program. *Pharmacoepidemiology and Drug Safety* 2019 Jan;28(1):16-24.
127. \* D'Arcy M, Stürmer T, **Lund JL**. The importance and implications of comparator selection in pharmacoepidemiologic research. *Current Epidemiology Reports* 2018 Sep;5(3):272-283.
128. Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, **Lund JL**, Patorno E, Slaughter JL, Wen X, Bennett D; ISPE Comparative Effectiveness Research Special Interest Group. Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). *Clinical Pharmacology and Therapeutics* 2018 Aug;104(2):239-241.
129. \* Cuthbertson CC, Kucharska-Newton A, Stürmer T, Faurot KR, Bandeen-Roche KL, Funk MJ, Palta P, **Lund JL**. Validating a Medicare Claims-Based Model to Classify Phenotypic Frailty in Older Adults. *Epidemiology* 2018 Jul;29(4):556-561.
130. Nishijima TF, Deal AM, **Lund JL**, Nyrop KA, Muss HB, Sanoff HK. The incremental value of a geriatric assessment-derived three-item scale on estimating overall survival in older adults with cancer. *Journal of Geriatric Oncology* 2018 Jul;9(4):329-336.

131. Smitherman AB, Anderson C, **Lund JL**, Bensen JT, Rosenstein DL, Nichols HB. Frailty and Comorbidities Among Survivors of Adolescent and Young Adult Cancer: A Cross-Sectional Examination of a Hospital-Based Survivorship Cohort. *Journal of Adolescent and Young Adult Oncology* 2018 Jun;7(3):374-383.
132. Kalbaugh CA, Loehr L, Wruck L, **Lund JL**, Matsushita K, Bengtson LGS, Heiss G, Kucharska-Newton A. Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study. *Journal of the American Heart Association* 2018 Apr 13;7(8).
133. Williams GR, Deal AM, **Lund JL**, Chang YK, Muss HB, Pergolotti M, Guerard EJ, Shachar SS, Wang Y, Kenzik K, Sanoff HK. Patient-Reported Comorbidity and Survival in Older Adults with Cancer. *The Oncologist* 2018 Apr;23(4):433-439.
134. Herzog MM, Marshall SW, **Lund JL**, Pate V, Mack CD, Spang JT. Trends in Incidence of ACL Reconstruction and Concomitant Procedures Among Commercially Insured Individuals in the United States, 2002-2014. *Sports Health*. 2018 Nov/Dec; 10(6): 523-53.
135. Naumann RB, Marshall SW, **Lund JL**, Gottfredson NC, Ringwalt CL, Skinner AC. Evaluating short- and long-term impacts of a Medicaid "lock-in" program on opioid and benzodiazepine prescriptions dispensed to beneficiaries. *Drug and Alcohol Dependence*. 2018 Jan 1;182:112-119.
136. \* Landi SN, Sandler RS, Pate V, **Lund JL**. No Increase in Acute Myocardial Infarction Risk in Proton Pump Inhibitor vs Histamine-2 Receptor Antagonist Users. *Gastroenterology* 2018 Mar;154(4):861-873.
137. Mohiuddin JJ, Deal AM, **Lund JL**, Carey LA, Baker BR, Zagar TM, Jones EL, Marks LB, Chen RC. Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. *JNCI Cancer Spectrum* (E-pub ahead of print: September 27, 2017).
138. \* Østgård LS, **Lund JL**, Nørgaard JM, Nørgaard M, Medeiros BC, Nielsen B, Nielsen OJ, Overgaard UM, Kallenbach M, Marcher CW, Riis AH, Sengeløv H. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National population-based Cohort Study. *Biology of Blood and Marrow Transplantation*. 2018 Feb;24(2):314-323.
139. **Lund JL**, Sanoff HK, Hinton SP, Muss HB, Pate V, Stürmer T. Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. *Cancer Epidemiol Biomarkers Prev*. 2018 Jan;27(1):41-49.
140. Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, **Lund JL**, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T, Zirpoli GR, Borges VF, Rosenberg LA, Bandera EV, Ambrosone CB, Palmer JR, Troester MA. Biology and etiology of young-onset breast cancers among premenopausal African American women: results from the AMBER Consortium. *Cancer Epidemiol Biomarkers Prev*. 2017 Dec;26(12):1722-1729.

141. **Lund JL**, Puhó EH, Szépligeti SK, Sorensen HT, Pedersen L, Ehrenstein V, Stürmer T. Conditioning on Future Exposure to Define Study Cohorts Can Induce Bias: The case of low-dose acetylsalicylic acid and risk of major bleeding. *Clinical Epidemiology*. 2017 Nov 23;9:611-626
142. Kinlaw AC, Stürmer T, **Lund JL**, Pedersen L, Daniels JL, Kappelman MD, Sørensen HT. Birth cohort effects on antibiotic prescribing during infancy. *Pediatrics*. 2017 Sep;140(3).
143. Garry EM, Buse JB, **Lund JL**, Pate V, Stürmer T. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. *Diabetes Obesity and Metabolism*. 2017 Dec;26(12):1722-1729.
144. Mariano C, **Lund JL**, Hinton SP, Htoo P, Muss HB, Reeder-Hayes KR. Measuring the Association Between Adjuvant Chemotherapy and Function-Related Adverse Events among Older Breast Cancer Patients. *Journal of Geriatric Oncology*. 2017 Jul;8(4):242-248.
145. DeBono N, Robinson WR, **Lund JL**, Tse CK, Moorman PG, Olshan AF, Troester MA. Race, menopausal hormone therapy, and invasive breast cancer in the Carolina Breast Cancer Study. *Journal of Women 's Health* 2018 Mar;27(3):377-386.
146. \* Guerard EJ, Deal AM, Chang YK, Williams GR, Nyrop KA, Pergolotti M, Muss HB, Sanoff HK, **Lund JL**. Frailty Index Developed from a Cancer-Specific Geriatric Assessment and the Association with Mortality among Older Adults with Cancer. *Journal of the National Comprehensive Cancer Network*. 2017 Jul;15(7):894-902.
147. Murphy CC, **Lund JL**, Sandler RS. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden? *Gastroenterology*. 2017 Jun;152(8):1809-1812.
148. Herzog MH, Marshall SW, **Lund JL**, Pate V, Mack CD, Spang JT. Increasing Incidence of ACL Reconstruction Among Adolescent Females in the United States, 2002-2014. *JAMA Pediatrics*. 2017 Aug 1;171(8):808-810.
149. Kalbaugh CA, Kucharska-Newton A, Wruck L, **Lund JL**, Selvin E, Matsushita K, Bengtson LS, Heiss G, Loehr L. Peripheral artery disease prevalence and incidence estimated from both outpatient and inpatient settings among Medicare fee-for-service beneficiaries in the Atherosclerosis Risk in Communities (ARIC) study. *Journal of the American Heart Association* 2017: 3;6(5).
150. **Lund JL**, Meyer AM, Deal AM, Choi BJ, Chang YK, Williams GR, Pergolotti M, Guerard EJ, Muss HB, Sanoff HK. Data Linkage to Improve Geriatric Oncology Research: A Feasibility Study. *The Oncologist*. 2017 Aug;22(8):1002-1005.
151. Hong JL, Henderson LM, Funk MJ, **Lund JL**, Buse J, Pate V, Sturmer T. Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. *Pharmacoepidemiology and Drug Safety*. 2017 Jun;26(6):666-675.
152. Gokhale M, Buse JB, Jonsson Funk M, **Lund J**, Pate V, Simpson RJ, Sturmer T. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. *Diabetes, Obesity, and Metabolism*. 2017 Jul;19(7):970-978.

153. Erichsen R, Horvath-Puho E, **Lund JL**, Dellon ES, Shaheen NJ, Pedersen L, Smith GD, Sørensen HT. Mortality and cardiovascular diseases risk in patients with Barrett's oesophagus: a population-based nationwide cohort study. *Alimentary Pharmacology and Therapeutics*. 2017 Apr;45(7):973-982.
154. Murphy CC, Sanoff HK, Stitzenberg KB, Baron JA, **Lund JL**, Sandler RS. Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease. *Journal of Cancer Epidemiology* 2017;2017:4024580.
155. Murphy CC, Sandler RS, Sanoff HK, Yang YC, **Lund JL**, Baron JA. Decrease in incidence of colorectal cancer among individuals 50 years or older following recommendations for population-based screening. *Clinical Gastroenterology and Hepatology*. 2017 Jun;15(6):903-909.
156. Kucharska-Newton A, Palta P, Burgard S, Griswold M, **Lund JL**, Capistrant B, Kritchevsky S, Bandeen-Roche K, Windham BG. Operationalizing frailty in the Atherosclerosis Risk in Communities (ARIC) Study cohort. *Journal of Gerontology: Medical Sciences*. 2017 72(3):382-388.
157. Sanoff HK, Chang YK, Reimers M, **Lund JL**. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries with Hepatocellular Carcinoma. *Journal of Oncology Practice*. 2017 13(3):e197-e206.
158. Hong JL, Funk MJ, Buse J, Henderson LM, **Lund JL**, Pate V, Stürmer T. Comparative effect of Initiating Metformin versus Sulfonylureas on Breast Cancer Risk in Older Women. *Epidemiology*. 2017 28(3):446-454.
159. Herzog MH, Marshall SW, Pate V, **Lund JL**, Spang JT. Cost of Outpatient Arthroscopic Anterior Cruciate Ligament Reconstruction Among Commercially Insured Patients in the United States, 2005-2013. *The Orthopaedic Journal of Sports Medicine*. 2017; 5(1): 1-8.
160. Mohiuddin JJ, Deal AM, Carey LA, **Lund JL**, Baker BR, Zagar TM, Jones EL, Marks LB, Chen RC. Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. *Journal of the American College of Surgeons*. 2016; 223(5):717-728.
161. Noone AM, **Lund JL**, Mariotto A, Cronin K, Deapen D, Warren JL. Comparison of SEER Treatment Data with Medicare Claims. *Medical Care* 2016; 54(9):e55-64.
162. Sanoff HK, Chang YK, **Lund JL**, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. *The Oncologist*. 2016; 21(9):1113-20.
163. Jiron M, Pate V, Hanson LC, **Lund JL**, Jonsson Funk M, Stürmer T. Trends in prevalence and determinants of potentially inappropriate prescribing in the US 2007-2012. *Journal of the American Geriatrics Society*. 2016; 64(4): 788-97.

164. Young JC, Sturmer T, **Lund JL**, Jonsson Funk M. Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data. *Pharmacoepidemiology and Drug Safety*. 2016; 25(7): 836-43.
165. Søgaard KK, Farkas DK, Pedersen L, **Lund JL**, Thomsen RW, Sørensen HT. Long-term Risk of Gastrointestinal Cancers in Persons with Gastric or Duodenal Ulcers. *Cancer Medicine* 2016; 5(6):1341-51.
166. **Lund JL**, Sturmer T, Sanoff HK. Comparative effectiveness of postoperative chemotherapy among older non-metastatic rectal cancer patients treated with preoperative chemoradiotherapy. *Journal of Geriatric Oncology* 2016; 7(3):176-86.
167. **Lund JL**, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Current Epidemiology Reports*. 2015; 2(4): 221-28.
168. **Lund JL**, Østgård LS, Prandoni P, Sorensen HT, Brown PD. Incidence, Determinants and the Transient Impact of Cancer Treatments on Venous Thromboembolism Risk among Lymphoma Patients in Denmark. *Thrombosis Research* 2015; 136(5): 917-23.
169. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, **Lund JL**, Pasricha S, Runge T, Schmidt M, Shaheen NJ, Sandler RS. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. *Gastroenterology* 2015;149(7): 1731-41
170. Sanoff HK, Chang YK, Stavas JM, Stürmer T, **Lund JL**. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. *Journal of the National Comprehensive Cancer Network* 2015; 13(9): 1102-10
171. Murphy CC, Harlan LC, **Lund JL**, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. *Journal of the National Cancer Institute* 2015; 107(10): 1-11.
172. Sanoff HK, Morris WL, Micheltree AL, Wilson S, **Lund JL**. Lack of Support and Information Regarding Long-Term Negative Effects in Survivors of Rectal Cancer. *Clinical Journal of Oncology Nursing* 2015; 19(4): 444-48.
173. Hall SA, Ranganathan G, Tinsley LJ, **Lund JL**, Kupelian V, Wittert GA, Kantoff PW, Morales A, Araujo AB. Population-based patterns of prescription androgen use in Saskatchewan, Canada, 1976-2008. *Pharmacoepidemiology and Drug Safety* 2014; 23(5): 498-506.
174. Søgaard KK, Erichsen R, **Lund JL**, Farkas DK, Sørensen HT. Cholangitis and Subsequent Gastrointestinal Cancer Risk: A Danish Population-Based Cohort Study. *Gut* 2014; 63(2): 356-61.
175. **Lund JL**, Cook SF, Allen JK, Carroll CF, Kappelman MD. Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn's disease in the United States. *Clinical Epidemiology* 2013; 5:501-12.

176. **Lund JL**, Froslev T, Deleuran T, Erichsen R, Nilsson T, Pedersen AN, Hoyer M. Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. *Clinical Epidemiology* 2013; 5:327-34.
177. **Lund JL**, Stürmer T, Sanoff HK, Brookhart MA, Sandler RS, Warren JL. Determinants of Adjuvant Oxaliplatin Receipt Among Older Stage II and III Colorectal Cancer Patients. *Cancer* 2013; 119: 2038-47.
178. **Lund JL**, Stürmer T, Harlan LC, Sanoff HS, Sandler RS, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. *Medical Care* 2013; 51(5): e27-34.
179. Butler EN, Chawla N, **Lund J**, Harlan LC, Warren JL, Yabroff KR. Patterns of colorectal cancer care in the United States and Canada: a systematic review. *Journal of the National Cancer Institute Monograph* 2013; 46: 13-35.
180. Chawla N, Butler EN, **Lund J**, Warren JL, Harlan LC, Yabroff KR. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. *Journal of the National Cancer Institute Monograph* 2013; 46: 36-61.
181. Dominguez RL, Crockett SD, **Lund JL**, Suazo LP, Davis PH, Martin C, Morgan DR. Gastric cancer incidence estimation in a resource-limited nation: use of endoscopy registry methodology. *Cancer Causes and Control* 2013; 24(2): 233-39.
182. Peery AF, Dellon ES, **Lund J**, Crockett SD, McGowan C, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of Gastrointestinal Disease in the United States, 2012. *Gastroenterology* 2012; 143(5):1179-87.
183. Yabroff KR, **Lund JL**, Kepka D, Mariotto A. Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. *Cancer Epidemiology, Biomarkers and Prevention*, 2011; 20(10): 2006-2014.
184. Federspiel JJ, Stearns S, van Domburg RT, Sheridan BC, **Lund JL**, Serruys PW. Risk-Benefit Trade-offs in Revascularization Choices. *EuroIntervention*. 2011; 6(8): 936-41.
185. Weiner BJ, Amick HR, **Lund JL**, Lee DS, Hoff TJ. Use of Qualitative Methods in Published Health Services and Management Research: A Ten-Year Review. *Medical Care Research and Review*. 2011; 68(1): 3-33.
186. **Lund JL**, Stürmer T, Porter C, Sandler RS, Kappelman MD. Thiazolidinedione use and ulcerative colitis related flares: an exploratory analysis of administrative data. *Inflammatory Bowel Diseases*. 2011; 17(3): 787-94.
187. **Lund JL**, Harlan LC, Yabroff KR, Warren JL. Should Cause of Death From the Death Certificate Be Used to Examine Cancer-Specific Survival? A Study of Patients with Distant Stage Disease. *Cancer Investigation*. 2010; 28(7):758-64.

188. **Lund JL**, Yabroff KR, Ibuka Y, Russell LB, Barnett PG, Lipscomb J et al. Inventory of data sources for estimating health care costs in the United States. *Medical Care*. 2009; 47: S127-S142.

#### LETTERS TO THE EDITOR

1. \* Su IH, Lund JL, Gaber CE, Sanoff HK, Strassle PD, Duchesneau ED. In Reply: Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs. *Oncologist* (Epub ahead of print: May 20, 2023). PMID: 37210593.
2. Chubak J, **Lund JL**. Noncancer comparators in cancer survivorship studies. *Cancer*. 2022 Aug 1;128(15):2994.
3. Mamtani R, **Lund J**, Hubbard RA: Considering the totality of evidence: Combining real-world data with clinical trial results to better inform decision-making. *Pharmacoepidemiology & Drug Safety* 30: 814-816, March 2021.
4. \* Shmuel S, Yang JY, Thai S, Webster-Clark MA, **Lund JL**. Assessing Clinical Trial Effects on Outcomes Among Pediatric and Adolescent and Young Adult (AYA) Patients With Cancer. *Cancer*. 2021; 127(4):648-649.
5. Kirkegård J, **Lund JL**, Mortensen FV, Cronin Fenton D. Reply to: "Design flaws in statins and pancreatic cancer research". *International Journal of Cancer*. 2019;145(5):1450-1451.
6. Li X, **Lund JL**, Toh S. Lower Cancer Incidence: Warfarin effect or Immortal Time Bias? *JAMA Internal Medicine* 2018; 178(4):584-5.
7. Murphy CC, Sanoff HK, Baron JA, Stitzenberg KB, Y. Yang C, Sandler RS, **Lund JL**. Re: Colorectal cancer incidence patterns in the United States, 1974—2013. *Journal of the National Cancer Institute*. 2017; 109(8): 104.
8. Sanoff HK, Chang YK, **Lund JL**, O'Neil B, Dusetzina SB. Immortal Time Bias or Sorafenib Effect in Elderly Patients with HCC? *Hepatology*. 2017; 66(2):678-679.
9. **Lund JL**, Montomoli J. Common Flaws in Pharmacoepidemiologic Study Design and Analysis *Journal of Clinical Oncology* 2013; 31(32):4161-2.
10. **Lund JL**, Stürmer T, Sørensen HT. Benefits and Risks of Aspirin Use. *JAMA* 2012; 308(11): 1088-89.

#### INVITED CONTRIBUTIONS AND OTHER WORKS

1. **Lund JL**, Lo Re V. Pharmacoepidemiology and Drug Safety's core concepts in pharmacoepidemiology section at 1 year: Where do we go from here? *Pharmacoepidemiology and Drug Safety* (In-Press).
2. **Lund JL**. Should machine learning be used to assess clinical trial data on older adults with cancer? *Counter. Hem Onc Today* (E-pub online: April 10, 2022). Available at:

<https://www.healio.com/news/hematology-oncology/20220404/should-machine-learning-be-used-to-assess-clinical-trial-data-on-older-adults-with-cancer>, accessed on June 1, 2023.

#### *MEDIA COVERAGE*

1. The Daily Tar Heel. Orange County sees highest life expectancy in North Carolina due to abundant resources. Published on April 12, 2023. Available at: <https://www.dailytarheel.com/article/2023/04/city-orange-county-north-carolina-life-expectancy-compared-to-south>, accessed on June 1, 2023.

#### *SELECTED ORAL PRESENTATIONS FROM SUBMITTED ABSTRACTS*

1. Bykov K, **Lund JL**, Patorno E, Franklin J, Girman C. Building Consensus on RWE Evaluation: Standardized Tool for Assessing Validity in RWE Studies of Medication Safety and Effectiveness. International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Halifax, Nova Scotia, Canada, August 25, 2023.
2. **Lund JL**, Garcia-Albeniz X, Maringe C, Gaber CE, Wyss R, Ghazarian A, Salas M. Invited Symposium – Cloning, Censoring, and Weighting — Oh My! Applications of Target Trial Emulation for Evaluating Cancer Interventions When Study Eligibility, Intervention Initiation, and Start of Follow-up Are Not Aligned. International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Copenhagen, Denmark, August 24, 2022.
3. Lesko C, Fox M, **Lund JL**, Jackson J, Ludema C, Ranapurwala S. Timeless person-time problems. Society for Epidemiologic Research Annual Meeting. Chicago, IL, June 15, 2022.
4. **Lund JL**. Real-World Data: Promises and Pitfalls in Turning Data to Evidence. 2022 ASCO Annual Meeting. Chicago, IL, June 6, 2022.
5. Hester LL, Seeger J, Davis K, Golozar A, Sansbury L, **Lund JL**. Concurrent Workshop - Using Real-world External Controls to Support Drug Approval: An Interactive Framework Using Oncology Trial and Real-world Data. *ICPE All Access Virtual Meeting*, August 24, 2021.  
Available through *Pharmacoepidemiology and Drug Safety* 2021; 30(S1): p.4.
6. **Lund JL**. Current Methodological Challenges and Future Directions for Frailty Measurement in Pharmacoepidemiology. Part of the symposium titled, “At the intersection of frailty and pharmacoepidemiology: Foundations, applications, and future directions”. *ICPE All Access Virtual Meeting*, December 8, 2020.  
Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): MY01.
7. **Lund JL**, Webster-Clark MA, Keil AP, Westreich D, Sturmer T, Sanoff HK. Transporting treatment effects from clinical trials to clinical practice using a hybrid study approach: The case of adjuvant FOLFOX versus 5FU for colon cancer treatment. *ICPE All Access Virtual Meeting*, September 16-17, 2020.  
Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): 115.
8. \* Webster-Clark MA, Keil AP, Sanoff HK, Stürmer T, Westreich D, **Lund JL**. Longitudinal cumulative dose: A novel measure to evaluate multiple dimensions of chemotherapy adherence over time. *ICPE All Access Virtual Meeting* September 16-17, 2020.

Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): 198.

9. Garry EM, Buse JB, Gokhale M, **Lund JL**, Pate V, Stürmer T. Implementation of the prevalent new user study design in the US Medicare population: Benefit versus harm. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 167.

10. \* Mayer SE, Pate V, Hanson LC, Jonsson Funk M, Faurot KR, Stürmer T, **Lund JL**. Improving claims-based frailty prediction in the Medicare population using STOPPFrail drug criteria. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 193.

11. Herzog MM, **Lund JL**, Pate V, Spang JT, Marshall SW. Association between fluoroquinolone use and anterior cruciate ligament injury in the United States. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 376.

11. Chubak JC, Newcomer S, **Lund JL**. Thinking beyond diagnosis, procedure, and drug codes: Shaping the future of epidemiologic research using electronic healthcare databases. *51<sup>st</sup> Annual Meeting of the Society for Epidemiologic Research*, Baltimore, MD, June 19-22, 2018.
12. **Lund JL**, Hinton SP, Stürmer T. Potential Pitfalls in Using the Beers Criteria to Identify Potentially Inappropriate Medications in the Context of an Index Event. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 13.

13. Kinlaw AC, Sorensen HT, **Lund JL**, Pedersen L, Daniels JL, Kappelman MD, Mack CD, Steiner MJ, Froslev T, Stürmer T. Antibiotic Prescribing During Infancy and Risk of Treated Airway Diseases Among Children Born in Denmark 2004–2012. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 25.

14. \* Hester LL, Brookhart MA, Stürmer T, **Lund JL**. Developing a Comorbidity Risk Prediction Model for Older Adults with Indolent Non-Hodgkin Lymphoma. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 209.

15. \* Yang JY, Sanoff HK, Sandler RS, Stürmer T, Jonsson Funk J, **Lund JL**. Does Proton-Pump Inhibitor Use Diminish Capecitabine Efficacy in Advanced Cancer Patients? *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 222.

16. \* D’Arcy ME, Stürmer T, **Lund JL**. Improving Identification of Incident Colorectal (CRC) Cancer and Differentiation by Cancer Site Using Claims Data and a Multistage, Machine Learning, Classification and Regression Tree (CART) Approach. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
- Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 445.
17. Garry EM, Buse JB, **Lund JL**, Pate V, Stürmer T. Pioglitazone and the Risk of Bladder Cancer in Older Adults with Type 2 Diabetes: A Comparison with a Clinically Meaningful Treatment Alternative. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
- Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 474.
18. Young JC, **Lund JL**, Dasgupta N, Funk MJ. Is Prior Opioid Tolerance Associated with Safer Use of Extended-Release Opioids? *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
- Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 486.
19. \* Herzog MM, Young JC, Marshall SW, Mack CD, Pate V, **Lund JL**. Oral Contraceptive Use and Anterior Cruciate Ligament Injury: An Active Comparator New User Cohort Study. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
- Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 553.
20. Young JC, **Lund JL**, Dasgupta N, Funk MJ. “Opioid Tolerance Prior to Initiation of High- Dose Oxycodone in Commercially-Insured Adults in the US, 2010-2014” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 20.
21. \* Hester LL, Park SI, **Lund JL**. “Predictors of Induction Chemoimmunotherapy Among Older US Adults with Follicular Lymphoma” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 28.
22. \* D’Arcy ME, Stürmer T, Meyer AM, Funk MJ, Sandler RS, Baron J, Troester M, **Lund JL**. “Validation of Claims-Based Definitions of Incident Colorectal Cancer (CRC) in a North Carolina (NC) Medicare Population” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 29.
23. Kinlaw AC, Sørensen HT, **Lund JL**, Pedersen L, Daniels JL, Kappelman MD, Stürmer T. “Birth Cohort Effects on Overall and Subtype- Specific Antibiotic Use Among Infants Born in Denmark 2004-2012” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 32.
24. Andrews E, Stürmer T, McGrath LJ, Funk MJ, **Lund JL**, Johannes CB, Gilseman AW, Powers C. “Exploring Innovative Methods to Conduct Validation Using United States Medicare

Administrative Claims Data” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 50.

25. Herzog MH, Marshall SW, Pate V, **Lund JL**, Spang JT. “Incidence and Trends in ACL Reconstruction Among Commercially-Insured Individuals in the United States, 2002-2013” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 252.

26. \* Htoo PT, Mariano CJ, Hinton SP, Hayes KR, Funk MJ, Stürmer T, **Lund JL**. “Propensity Score Methods for Subgroup Analyses: Investigating Covariate Balance” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 477.

27. \* Landi SN, **Lund JL**, Pate V, Sandler RS. “Association of Proton Pump Inhibitor Use and Acute Myocardial Infarction Among Privately Insured Adults, 2001-2014” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 491.

28. Gokhale MN, Buse JB, Funk MJ, **Lund JL**, Simpson R, Stürmer T. “Comparative Incidence of Cardiovascular Events in Older Adults Initiating DPP-4 Inhibitors versus Other Antidiabetic Drugs” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 510.

29. **Lund JL**, Stürmer T, Keil AP, Picciotto S, Hernan M. “Healthy Workers and Healthy Users: Comparing Approaches to Mitigate Confounding and Selection Bias in Occupational and Pharmaco-Epidemiology” *2016 Epidemiology Congress of the Americas*, Miami, FL June 21-24, 2016.

30. **Lund JL**, Lash TL, Stürmer T, Aquavella J, Stovring H, Maclure M, Laden F, Lo Re V, Werler M, Sacks S. Does the Increasing Specialization of Epidemiologic Societies Ensure the Best Future for Our Profession? *31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Boston, MA August 22-26, 2015.

Available through *Pharmacoepidemiology and Drug Safety* 2015; 24(S1).

31. **Lund JL**, Sanoff HK, Stürmer T. “Controlling for markers of frailty in cancer comparative effectiveness research among older adults” *31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Boston, MA August 22-26, 2015.

Available through *Pharmacoepidemiology and Drug Safety* 2015; 24(S1): 2.

32. **Lund JL**, Stürmer T, Horvath-Puhó E, Szepligeti S, Pedersen L, Ehrenstein V, Baron JA. “Avoiding ‘Crystal Ball’ Epidemiology: The Case of Low-Dose Aspirin and Major Bleeding”

30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan, October 24-27, 2014.

Available through *Pharmacoepidemiology and Drug Safety* 2014; 23(S1): 174.

33. **Lund JL**, Østgård LS, Prandoni P, Sorensen HT, Brown P. “Incidence and Predictors of venous Thromboembolism Among Lymphoma Patients in Denmark: A Nationwide Population-Based Cohort Study” *American Society of Hematology 55<sup>th</sup> Annual Meeting*, New Orleans, LA, December 5-10.

Available through *Blood* 2013; 122(21): 934

34. **Lund JL**, Schmidt M, Stürmer T, Riis AH, Pedersen L, Sorensen HT. “Do Statins Reduce Short-Term Mortality among Patients Hospitalized with Perforated Peptic Ulcers?” *29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 25-28.

Available through *Pharmacoepidemiology and Drug Safety* 2013; 22(S1): 392

#### SELECTED POSTER PRESENTATIONS

1. **Lund JL**, Shmuel S, Rice C, Pate V, Thorpe CT, Hanson LC, Niznik JD. Validating Medicare claims-based algorithms for deprescribing of benzodiazepines using a novel linkage with electronic health records data. *39<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Halifax, Nova Scotia, Canada, August 23-27, 2023.
2. **Lund JL**, Webster-Clark MA, Bratton EW. Assessing the representativeness of trial populations for contemporary real-world cancer patients: A case study of adjuvant chemotherapy for colon cancer. *American Society of Clinical Oncology (ASCO) Quality Care Symposium*, September 24-25, 2021 (Hybrid Meeting: Boston, MA, USA).
3. **Lund JL**, Webster-Clark MA, Sturmer T, Westreich D, Sanoff HK, Keil AP. A picture is worth 1000 words: Visual tools to guide transport of trial results to real-world populations. *ICPE All Access Virtual Meeting* September 16-17, 2020.

Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): 374.

4. Rivera DR, Gokhale MN, Reynolds MW, Andrews EB, Chun DC, Haynes K, Jonsson-Funk ML, Lynch KE, **Lund JL**, Strongman H, Raman SR. Linking electronic health data in pharmacoepidemiology: Guidance for assessing appropriateness and feasibility. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 88.

5. Cole AL, Wood WA, Muluneh B, **Lund JL**, Lafata JE, Dusetzina SB. Predictors of tyrosine kinase inhibitor treatment for chronic myeloid leukemia. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 104.

6. \* Webster-Clark MA, **Lund JL**, Pate V. When prescriptions fall short: Using CPT codes to augment warfarin prescriptions in claims. *34<sup>th</sup> International Conference on*

*Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 110.

7. \* D'Arcy M, Stürmer T, **Lund JL**. A flexible approach to evaluating the validity of commonly used claims-based cancer algorithms. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 124.

8. **Lund JL**, Meng K, Urick BY, Farley JF, Amin K, Wheeler SB, Reeder-Hayes KE, Trogon JG. Changes in diabetes medication adherence in older cancer patients versus matched cancer-free cohorts: A difference-indifference analysis. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 157.

9. Wang T, Gower EW, **Lund JL**, Jonsson Funk M, Pate V, Buse JB, Stürmer T. Multiple imputation of clinical variables in FFS Medicare population. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 165.

10. Jiron M, Pate V, Hanson LC, **Lund JL**, Jonsson Funk M, Stürmer T. Potential omissions of angiotensin inhibition treatment among older US adults after an acute myocardial infarction. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 291.

11. Jiron M, Pate V, Hanson LC, **Lund JL**, Jonsson Funk M, Stürmer T. Potential omissions of oral anticoagulant among older US adults with newly diagnosed atrial fibrillation. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 292.

12. \* Chun DS, Hinton SP, **Lund JL**. Potentially inappropriate medication use and emergency department visits in older women diagnosed with breast cancer initiating chemotherapy. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 295.

13. \* Shmuel S, **Lund JL**, Alvarez C, Hsu CD, Palta P, Kucharska-Newton AM, Nelson AE, Golightly YM. Polypharmacy and frailty in a longitudinal community-based cohort study. *34<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 296.

14. **Lund JL**, Pate V, Jiron M, Hanson LC, Shmuel S, Webster-Clark MA, Farley JF, Stürmer T. Improving population-level PIM exposure metrics using Medicare claims data. *34<sup>th</sup> International*

*Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague Czech Republic, August 22-26, 2018.*

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 297.

15. **Lund JL**, Webster-Clark MA, Sanoff HK, Keil AP, Westreich D, Brookhart MA, Stürmer T. Generalizing randomized clinical trial results to calendar-year specific cohorts of older stage II-III colon cancer patients initiating adjuvant chemotherapy. *51<sup>st</sup> Annual Meeting of the Society for Epidemiologic Research*, Baltimore, MD, June 19-22, 2018.
16. \* Mitchell AP, Kinlaw AC, Hinton SP, Sanoff HK, Basch E, **Lund JL**. Cancer Patients Receive Higher-Priced Chemotherapy When Treated in Private Practice Compared to Academic Institutions. *Academy Health Annual Research Meeting*, Seattle, WA, USA, June 24-26.
17. Mitchell AP, Winn AN, **Lund JL**, Dusetzina SB. Duration of Physician-Industry Relationships and Prescribing Changes in Oncology. *2018 American Society for Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL, USA, June 1-4, 2018.
18. Nishijima TF, Deal AM, **Lund JL**, Nyrop K, Muss HB, Sanoff HK. The value of inflammatory markers in predicting overall survival in older adults with cancer. *2018 American Society for Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL, USA, June 1-4, 2018.
19. Williams GR, Dunham L, Chang YK, Deal AM, Pergolotti M, **Lund JL**, Guerard E, Kenzik K, Muss HB, Sanoff HK. Geriatric assessment to predict hospitalization frequency and long-term care utilization in older adult cancer survivors. *2018 American Society for Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL, USA, June 1-4, 2018.
20. **Lund JL**, Hinton SP, Hsu C, Stürmer T, Reeder-Hayes KE, Sanoff HK. Association between concomitant hydrochlorothiazide use and neutropenia-related hospitalizations among older breast and colon cancer patients treated with chemotherapy. *2018 American Society for Preventive Oncology*, New York, NY, USA, March 10-12, 2018.
21. Zhang HT, McGrath LJ, Ellis AR, Wyss R, **Lund JL**, Stürmer T. Reducing Unmeasured Confounding by Frailty Through Restriction When Estimating Influenza Vaccine Effectiveness in Older Adults. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 531.

22. Htoo P, Gokhale M, Wyss R, **Lund JL**, Pate V, Jonsson Funk M, Buse JB, Stürmer T. Performance of Confounder Summary Scores in Estimating Subgroup Effects in Comparative Effectiveness Research. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 492.

23. Suarez EA, **Lund JL**, Doll KM, Robinson WR. Predicting Laterality of Oophorectomy in Administrative Data with Bundled CPT Codes. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 303.

24. \* Webster-Clark MA, Sanoff HK, Stürmer T, **Lund JL**. Can We Generalize? An Example of Older Adults with Metastatic Colorectal Cancer. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.  
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 145.
25. \* Benfield HC, Sanoff HK, **Lund JL**. Describing Performance Status Changes in Older Adults During Adjuvant Chemotherapy. *33<sup>rd</sup> International Conference on Pharmaco-epidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.  
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 168.
26. \* Chun DS, Faso AM, **Lund JL**. Findings from a Pharmacist-Led Medication Reconciliation for Cancer Patients Initiating a New Cycle of Chemotherapy. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.  
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 172.
27. \* Mayer SE, Tan HJ, Hinton SP, Hester LL, Stürmer T, Faurot KR, Jonsson Funk M, Sanoff HK, **Lund JL**. Medicare Claims-Based Measures of Poor Physical Function and Associations with Treatment and Mortality in Older Colon Cancer Patients. *33<sup>rd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.  
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 174.
28. \* Cuthbertson CC, Kucharska-Newton A, Stürmer T, Faurot KR, Bandeen-Roche KL, Funk MJ, Palta P, **Lund JL**. Validating a Medicare Claims-Based Model to Classify Phenotypic Frailty in Older Adults. 21<sup>st</sup> International Association of Gerontological Societies (IAGG) World Congress of Gerontology and Geriatrics, San Francisco, CA July 23-27, 2017.  
Available through *Innovation in Aging*, 2017; 1(Supp 1): 381.
29. Kinlaw AC, Sørensen HT, **Lund JL**, Mack CD, Pedersen L, Daniels JL, Kappelman MD, Stürmer T. “The Impact of Birth Season on Time to First Antibiotic Use Among Infants Born in Denmark 2004-2012” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.  
Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 68.
30. Zhang HT, McGrath LJ, Ellis AR, Wyss R, **Lund JL**, Stürmer T. “Improving Short-Term Mortality Prediction Using Timing of Acute Comorbidities During Lookback” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.  
Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 140.
31. **Lund JL**, Hinton SP, Sanoff HK, Pate V, Jirón M, Burkhart JI, Muss HB, Stürmer T. “Patterns and Predictors of Potentially Inappropriate Medication Use in Older Breast, Colon, and Lung Cancer Patients in the United States” *32<sup>nd</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.  
Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 374.

32. **Lund JL**, Murphy CC, Peacock Hinton S, Sanoff HK, Stürmer T. “Evaluating heterogeneity of adjuvant chemotherapy effectiveness among older adults diagnosed with stage III colon cancer” *2016 Epidemiology Congress of the Americas*, Miami, FL June 21-24, 2016.
33. **Lund JL**, Sanoff HK, Stürmer T. “Identifying heterogeneity of comorbid diabetes among older colon cancer patients: A latent class analysis” *15<sup>th</sup> Annual Meeting of the International Society for Geriatric Oncology*, Prague, Czech Republic November 12-14, 2015.  
Available through *Journal of Geriatric Oncology* 2015; 6(S1): S74.
34. **Lund JL**, Stürmer T, Sanoff HK. “Comparative effectiveness of contemporary adjuvant chemotherapy approaches among older rectal cancer patients” American Society Clinical Oncology Annual Meeting, Chicago, IL, May 29-June 2, 2014.  
Available through the *Journal of Clinical Oncology* 2014; 32(15): 3579
35. **Lund JL**, Stürmer T, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. “Influence of Patient, Physician, and Hospital Characteristics on Oxaliplatin Receipt among Older Stage II and III Colorectal Cancer Patients in the US” *28<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Barcelona, Spain August 23-26, 2012  
Available through *Pharmacoepidemiology and Drug Safety* 2012; 21(S3): 155
36. **Lund JL**, Erichsen R, Horvath-Puho E, Pedersen L, Davey-Smith G, Sorensen HT. “Mortality and the Risk of Cardiovascular Events in Barrett’s Esophagus.” 46<sup>th</sup> Society of Epidemiologic Research Annual Meeting Boston, MA June 18-21, 2012  
Available through *American Journal of Epidemiology* 2013; 177(Suppl 11): 151-S
37. **Lund JL**, Erichsen R, Frøslev T, Stürmer T, Sørensen HT. ”Use of Hospital Discharge Data To Monitor Trends in Chemotherapy Use among Individuals Diagnosed with Stage III Colon Cancer in Denmark, 2004–2009” *28<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Barcelona, Spain August 23-26, 2012  
Available through *Pharmacoepidemiology and Drug Safety* 2012; 21(S3): 992
38. **Lund JL**, Cook SF, Allen JK, Kappelman MD. “Patterns of 6-Mercaptopurine and Azathioprine Maintenance Therapy among Commercially Insured Individuals Diagnosed with Crohn’s Disease in the US” *28<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Barcelona, Spain August 23-26, 2012  
Available through *Pharmacoepidemiology and Drug Safety* 2012; 21(S3): 993
39. **Lund JL**, Stürmer T, Brookhart MA. “Nesting matters: A comparison of methods for analyzing non-nested clusters using the SEER-Medicare database” *45<sup>th</sup> Society of Epidemiologic Research Annual Meeting* Minneapolis, MN June 27-30, 2012  
Available through *American Journal of Epidemiology* 2012; 175(Suppl 11): S18
40. **Lund JL**, Stürmer T, Sanoff HK, Sandler RS, Brookhart MA, Warren JL, Harlan LC. “Patterns of On- and Off-Label Oxaliplatin Use among Stage II and III Colorectal Cancer Patients in 2005” *27<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Chicago, IL August 14-17, 2011  
Available through *Pharmacoepidemiology and Drug Safety* 2011; 20(S1): 269

41. **Lund JL**, Stürmer T, Harlan LC, Sandler RS, Sanoff HK, Brookhart MA, Warren JL. “Validation of chemotherapy drugs and combinations in Medicare data” *Third Annual North American Congress of Epidemiology* Montreal, Quebec Canada June 21-24, 2011  
Available through *American Journal of Epidemiology* 2011; 173(Suppl): S207
42. **Lund JL**, Stürmer T, Sandler RS, Sanoff HK, Harlan LC, Warren JL. “Validation of specific chemotherapy drugs in Medicare data” *American Society of Clinical Oncology Annual Meeting* Chicago, IL June 3-7, 2011  
Available through *Journal of Clinical Oncology*, 2011; 29 (15 Suppl): 6012
43. **Lund JL**, Dusetzina S, Gaynes B, Hansen R, and Funk MJ. ”Patterns and predictors of pharmacotherapy after hospitalization for major depression” *26th International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment* Providence, RI August 19-22, 2010  
Available through *Pharmacoepidemiology and Drug Safety* 2010; 19(S1): 105
44. Crockett S, **Lund JL**, Dominguez R, Morgan D “Use of an Endoscopy Database as a Gastrointestinal Cancer Registry Surrogate in a Resource-Limited Nation: Experience of the Western Honduras Gastric Cancer Project. 74th Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology San Diego, CA October 23-28, 2009  
Available through *American Journal of Gastroenterology* 2009, 104(Suppl 3): S51
45. **Lund JL**, Stürmer T, Porter C, Sandler RS, Kappelman MD. ”Thiazolidinedione use and ulcerative colitis related flares: an analysis of administrative data” *25<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment* Providence, RI August 16-19, 2009  
Available through *Pharmacoepidemiology and Drug Safety* 2009; 18(S1): 357
46. **Lund JL**, Stürmer T, Porter C, Sandler RS, Kappelman MD. ”Thiazolidinedione use and ulcerative colitis related flares: a claims database analysis” *42nd Society of Epidemiologic Research Annual Meeting Anaheim, CA* June 23-26, 2009  
Available through *American Journal of Epidemiology* 2009; 169(Suppl): S13

#### INVITED PRESENTATIONS

1. Target trial emulation using real-world data. GSK Value, Evidence, and Outcomes Seminar Series. Tuesday, June 20, 2023.
2. Methodological Challenges for Pharmacoepidemiologic Studies of Geriatric Cancer Care. Student International Society for Pharmacoepidemiology (SISPE) Webinar. Thursday, May 25, 2023.
3. Applying Real-World Data (RWD) for Oncology Research: Observational Study Design and Analytic Methods. COTA Healthcare Education Seminar. Thursday, May 18, 2023.
4. Understanding the utilization and effectiveness of cancer treatment in clinical practice. Opponent presentation – for PhD thesis defense of Erwei Zeng, Karolinska Institutet. Friday, May 12, 2023.
5. A basic introduction to target trial emulation using the clone-censor-weight method. University of Maryland Baltimore, School of Pharmacy, Methods Clinic. Monday, April 10, 2023.

6. Capturing vital status in multi-site studies of individuals with advanced cancer: Data sources and methods. Harvard Medical School, Center for Palliative Care, Research Methods in Supportive Oncology. Tuesday, January 24, 2023.
7. Quantifying chemotherapy delivery using longitudinal cumulative dose: An analysis of women initiating chemotherapy for early-stage breast cancer. Geriatric Oncology Symposium, University of North Carolina (UNC) Linebeger Comprehensive Cancer Center. Friday, December 2, 2022.
8. Real-world data for cancer research in North Carolina: An introduction to the UNC Cancer Information and Population Health Resource (CIPHR). McGill University. May 11, 2022.
9. Transporting Treatment Effects from Randomized Trials to Real-World Target Populations. Workshop. Karolinska Institutet. November 8, 2022.
10. Transporting Treatment Effects from Randomized Trials to Real-World Target Populations. Workshop. Karolinska Institutet. November 16, 2021.
11. Designing external control arm studies: Overview and interactive case study. UNC Center for Pharmacoepidemiology Methods Symposium. October 29, 2021.
12. Assessing the External Validity of Trial Results: Applications in Oncology. Johns Hopkins University, Center for Drug Safety and Effectiveness Seminar. April 12, 2021.
13. Predicting life expectancy in older adults with advanced cancer. Geriatric Oncology Symposium. Virtual Meeting. November 20, 2020.
14. Who benefits and how much in the real world? Transporting treatment effects from randomized trials to real world patient populations. UNC Gastrointestinal Epidemiology Seminar. November 4, 2020.
15. Who benefits and how much in the real world? Transporting treatment effects from randomized trials to real world patient populations. UNC Center for Pharmacoepidemiology Methods Symposium. Virtual Meeting. November 2, 2020.
16. Enhancing hybrid study designs for comparative effectiveness research. Research Triangle Symposium. RTI International, Research Triangle Park, NC, May 7, 2019.
17. The role of frailty in observation studies evaluating the comparative effectiveness and safety of medical interventions in older adults. Wake Forest Clinical Translational Sciences Institute (CTSI) Methods Conference on Emerging Methods in Translational Science: Challenges and Opportunities Across the Lifespan, Winston Salem, NC, November 9, 2018.
18. Potential medication-related problems among older adults newly diagnosed with cancer. HealthPartners Institute Seminar, Minneapolis, MN, August 14, 2018.
19. Opportunities for collaboration between LSHTM and UNC: Data resources, faculty and student interests, and a pilot collaborative project. Electronic Health Records Group Research Meeting, Department of Epidemiology, London School of Hygiene and Tropical Medicine, London, England, July 18, 2017.
20. Alternative approaches for evaluating the comparative effectiveness of cancer therapies using real world data. Epidemiology Seminar Series, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada, January 16, 2017.
21. Evaluating the comparative effectiveness of medical interventions: Contributions from pharmacoepidemiology. GlaxoSmithKline, London, England, November 16, 2016.

22. Introduction to propensity score methods. Invited presentation to the Danish Epidemiological Society via webinar, February 8, 2016.
23. Improving the measurement of patient frailty and comorbidity using administrative data. Invited presentation at the Lineberger Comprehensive Cancer Center, Cancer Outcomes Research Program Seminar, Chapel Hill, NC, November 18, 2014.
24. Improving outcomes for older cancer patients through pharmacoepidemiologic research. Invited presentation at the Lineberger Comprehensive Cancer Center Annual Scientific Retreat, Chapel Hill, NC, May 14, 2014.
25. State of the art pharmacoepidemiological study designs for post-approval risk assessment. Invited presentation at the Cardiac Safety Research Consortium, COPD Think Tank, Silver Spring, MD, USA. March 6, 2014.
26. In the Pursuit of Happiness (and Data)... Living and working as a Postdoc in Denmark. Invited lecture at the University of Kentucky, Department of Pharmacy Practice and Science, Lexington, KY, USA. January 31, 2013.

## **TEACHING RECORD**

### *COURSES*

- |   |                             |
|---|-----------------------------|
| Lead Instructor, “Epidemiologic Research Using Healthcare Databases”<br>3 credit hours; ~37 students enrolled<br>Department of Epidemiology, Gillings School of Global Public Health<br>University of North Carolina at Chapel Hill | Spring 2015, 17, 19, 21, 23 |
| Co-Instructor, “Epidemiology Research Methods: Proposal Writing”<br>3 credit hours; 8 students in small group<br>Department of Epidemiology, Gillings School of Global Public Health<br>University of North Carolina at Chapel Hill | Fall 2020                   |
| Lead Instructor, “Pharmacoepidemiology of Older Adults”<br>2 credit hours; 11 students enrolled<br>Department of Epidemiology, Gillings School of Global Public Health<br>University of North Carolina at Chapel Hill               | Spring 2016                 |
| Lead Instructor, “Professional Development for Epidemiology Students”<br>1 credit hour; 12 students enrolled<br>Department of Epidemiology, Gillings School of Global Public Health<br>University of North Carolina at Chapel Hill  | Spring 2015                 |
| Small Group Instructor, “Evidence Based Medicine”<br>8 students enrolled<br>Physician Assistant Program, Duke University<br>Course Director: Dr. Perri Morgan   | Fall 2011                   |
| Small Group Co-Instructor, “Clinical Epidemiology”<br>20 students enrolled  | Fall 2011                   |

School of Medicine, University of North Carolina at Chapel Hill  
Course Director: Dr. Jeffrey Sonis

*SHORT COURSES*

Instructor, “Transporting Treatment Effects from Randomized Trials to Target Populations” April 2023  
3-day course; 25 students enrolled  
Institute of Environmental Medicine  
Karolinksa Institutet, Stockholm, Sweden

Lead Instructor, “Applying Real-World Data (RWD) for Cancer Outcomes Research: Jul-Aug 2021  
Observational Study Design and Analytic Methods”  
US Food and Drug Administration, Virtual Training

Co-Instructor, “Intermediate Pharmacoepidemiology” 2017, 18, 19, 20, 21  
Pre-conference course, International Conference on Pharmacoepidemiology and Therapeutic Risk  
Management  
Montreal, Canada (August 2017), Prague, Czech Republic (August 2018), Philadelphia, USA  
(August 2019), Virtual Meeting (August 2020, August 2021)  
Co-Instructors: Michele Jonsson Funk, Til Stürmer, and Sudha Raman

Co-Instructor, “Introduction to Pharmacoepidemiology” 2015, 16, 17  
Pre-conference course, International Conference on  
Pharmacoepidemiology and Therapeutic Risk Management  
Boston, MA (August 2015), Baltimore, MD (April 2016), Dublin, Ireland (August 2016),  
Montreal, Canada (August 2017)  
Co-Instructors: Almut Winterstein and Tobias Gerhard

Co-Instructor, “Pharmacoepidemiology and Comparative Effectiveness Research” Summer 2016, 18, 24  
Aarhus University, Department of Clinical Epidemiology, Aarhus, Denmark  
Co-Instructor: Dr. Til Stürmer

Co-Instructor, “Issues and Methods in Pharmacoepidemiology” Summer 2011, 12, 15  
Aarhus University, Department of Clinical Epidemiology, Aarhus, Denmark  
Co-Instructor: Dr. Til Stürmer

*GUEST LECTURES*

Climate Change and Cancer Care Delivery April 2024  
EPID 771: Cancer Survivorship and Outcomes  
Department of Epidemiology, University of North Carolina at Chapel Hill

Target Trial Emulation Using Real-World Data April 2023  
EPID 765: Introduction to Pharmacoepidemiology  
Department of Epidemiology, University of North Carolina at Chapel Hill

Geriatric Oncology and Pharmacoepidemiology Fall 2015, 16, 17

EPID 771: Cancer Epidemiology: Survivorship and Outcomes  
Department of Epidemiology, University of North Carolina at Chapel Hill

Pharmacoepidemiology and Cancer Etiology Spring 2015, 16, 17  
EPID 770: Cancer Epidemiology and Pathogenesis  
Department of Epidemiology, University of North Carolina at Chapel Hill

Instrumental Variables: Theory and Application Fall 2014  
Research Seminar, Department of Clinical Epidemiology  
Aarhus University Hospital, Aarhus, Denmark

Methodological issues when using medication adherence as an exposure Spring 2014  
(or covariate) in comparative effectiveness research  
NC TraCS, University of North Carolina at Chapel Hill

Propensity Score Methods; Introduction and Application Spring 2014  
Journal Club Lecture, Department of Clinical Epidemiology  
Aarhus University Hospital, Aarhus, Denmark

An Introduction to Directed Acyclic Graphs: Theory and Application Winter 2013  
Journal Club Lecture, Department of Clinical Epidemiology  
Aarhus University Hospital, Aarhus, Denmark

Pharmacoepidemiology in Denmark Winter 2013  
Special topics in Epidemiology (Course 701)  
Department of Pharmaceutical Practice and Policy  
University of Kentucky, Lexington, KY

Validation Studies and Research in Denmark Winter 2013  
Introduction to Pharmacoepidemiology (EPID 765)  
Department of Epidemiology  
University of North Carolina, Chapel Hill, NC

Cancer Epidemiology Fall 2012  
Cancer Module, Department of Molecular Medicine  
Aarhus University, Aarhus, Denmark

Introduction to Propensity Score Methods Fall 2012  
Journal Club Lecture, Department of Clinical Epidemiology  
Aarhus University Hospital, Aarhus, Denmark

Recurrent Events: An Introduction to Concepts and Analysis Spring 2012  
Journal Club Lecture, Department of Clinical Epidemiology  
Aarhus University Hospital, Aarhus, Denmark

*GRADUATED PHD STUDENTS (AS CHAIR OF DISSERTATION COMMITTEE)*

1. Emilie Duchesneau, PhD; Graduated May 2023  
Dissertation title: Validation of a Medicare claims-based frailty index for identifying longitudinal changes in frailty in older adults
2. Jeff Yang, PhD; Graduated May 2023  
Dissertation title: Treat to Target Monitoring Colonoscopy in Patients Living with Inflammatory Bowel Disease (IBD): Utilization and Assessment of Methods for Evaluating Effectiveness Among Patients Treated for IBD in the United States
3. Sydney Thai, PhD; Graduated December 2022  
Dissertation title: Frailty Screening and Impairment Patterns in Older Adults with Cancer: A Dissertation using the Cancer Aging and Resilience Evaluation (CARE) Registry
4. Christine Hsu, PhD, PharmD; Graduated December 2022  
Dissertation title: Hepatocellular Carcinoma Surveillance Trends in Individuals with Cirrhosis in North Carolina, 2010-2018
5. Charles Gaber, PhD; Graduated May 2022  
Dissertation title: The comparative effectiveness of trimodal therapy versus definitive chemoradiation in older adults with locally advanced esophageal cancer
6. Danielle Chun, PhD; Graduated December 2020  
Dissertation title: Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma
7. Shahar Shmuel, PhD; Graduated August 2020  
Dissertation title: Anticholinergic and Sedative Drug Load in Older Adults
8. Michael Webster-Clark, PhD, PharmD; Graduated: May 2019  
Dissertation title: Can We Really Rely on RE-LY? Contrasting Clinical Trial Transport and Observational Analyses
9. Laura Hester, PhD, MPH; Graduated: August 2017  
Dissertation title: Patterns and Prediction of Competing Causes of Mortality among Older Adults with Indolent Non-Hodgkin Lymphoma
10. Monica D'Arcy, PhD, MS; Graduated: December 2016  
Dissertation title: Exploring the an/depressant colorectal cancer association in administrative data: Negative controls, active comparators and algorithms

*GRADUATED MSCR STUDENTS (AS PRIMARY OF SECONDARY READER)*

1. Christopher Jensen, MD, MSCR; Graduate May 2023  
Thesis title: Functional status impacts on treatment receipt and outcomes among older adults newly diagnosed with multiple myeloma
2. Ibaro Zambrano, MD, MSCR; Graduated August 2021  
Thesis title: Patterns of Multidisciplinary care in low and intermediate risk prostate cancer: A contemporary population-based analysis

3. Benjamin Wu, PharmD, MSCR; Graduated May 2020  
Thesis title: Comparative Effectiveness of Primary Antimyeloma Regimens in Transplant-Ineligible Newly-Diagnosed Multiple Myeloma Medicare Beneficiaries
4. Stephanie Lumpkin, MD, MSCR; Graduated May 2020  
Thesis title: Emergency Department Opioid Prescribing Variation After Discharge Following Major Surgery
5. Daniel Richardson, MD, MSCR; Graduated May 2020  
Thesis title: ASXL1mutSRSF2mut Acute Myeloid Leukemia: A Rare But Distinct Subpopulation with Dismal Outcomes

*CURRENT PHD STUDENTS*

- \* Denotes MSPH/PhD student
- \*\* Denotes primary co-mentor

  1. Xiaomeng (Olivia) Chen, MS; 2022-
  2. Bria Carmichael, MPH; 2022-
  3. Jeanny Wang, MS\*\*; 2022-
  4. Disha Subramaniam, MA; 2021-
  5. Joyce Pak, MPH, 2020-
  6. I-Hsuan (Claire) Su, MS; 2020-
  7. Courtney Schlusser, MPH; 2019-

*CURRENT JUNIOR FACULTY MENTEES*

1. Swathi Eluri: Faculty advisor on NIDDK K23 DK131338  
Title: Approaches and Outcomes of Shared Decision-making and Patient Centered Care Delivery in Barrett's Esophagus  
Role: Faculty Advisor
2. Josh Niznik: Co-mentor on NIA K08 AG071794-01  
Title: Deprescribing Bisphosphonates in Older Nursing Home Residents with Dementia  
Role: Co-Mentor
3. Nadja Vielot: Co-mentor on NCATS UL1TR002489-03S6  
Title: Effectiveness of Recombinant Herpes Zoster Vaccine in Older Adults  
Role: Co-Mentor
4. Eboneé Butler: Member of UNC Epidemiology departmental mentoring committee  
Role: Departmental mentor
5. Chantel Martin: Member of UNC Epidemiology departmental mentoring committee  
Role: Departmental mentor
6. Anthony Matthews: Member of Karolinska Institut mentoring team  
Role: External mentor
7. Anne Butler: Member of mentoring team (based at Washington University at St. Louis)

Role: External mentor

*PAST POST-DOCTORAL FELLOWS*

1. Matthew LeBlanc: 2021-2022
2. Shahar Shmuel: 2020-2022
3. Michael Webster-Clark: 2019-2021
4. Jessica Islam: 2019-2021

*MASTER'S COMMITTEE MEMBER*

1. Nathan DeBono, MSPH (Epidemiology); Graduated: 2016
2. Jeff Yang, MSPH (Epidemiology); Graduated: 2019

*DOCTORAL DISSERTATION COMMITTEE MEMBER*

1. Jin Liern-Hong, PhD (Epidemiology); Graduated: 2015
2. Xin Zhou, PhD (Biostatistics); Graduated: 2015
3. Mugdha Gokhale, PhD (Epidemiology); Graduated: 2016
4. Corey Kalbaugh, PhD (Epidemiology); Graduated: 2016
5. Alan Kinlaw, PhD (Epidemiology); Graduated: 2016
6. Caitlin Murphy, PhD (Epidemiology); Graduated: 2016
7. Lynn Chollet-Hinton, PhD (Epidemiology); Graduated: 2017
8. Rebecca Naumann, PhD (Epidemiology); Graduated: 2017
9. Mihaela Georgieva, PhD (Health Policy and Management); Graduated: 2018
10. Elizabeth Garry (Epidemiology); Graduated: 2018
11. Ashley Cole (Department of Pharmaceutical Outcomes and Policy); Graduated: 2018
12. Jane Der (Epidemiology/Biostatistics); Graduated: 2019
13. Danielle Gartner (Epidemiology); Graduated: 2019
14. Chelsea Anderson (Epidemiology); Graduated: 2019
15. Liz Suarez (Epidemiology); Graduated: 2019
16. Joseph Engeda (Epidemiology); Graduated: 2019
17. Paula Strassle (Epidemiology); Graduated: 2019
18. Kristen Richetti-Masterson (Epidemiology); Graduated: 2019
19. Rachael Billock (Epidemiology); Graduated: 2020
20. Veeral Saraiya (Epidemiology); Graduated: 2021
21. Sophie Mayer (Epidemiology); Graduated 2022
22. Jonathan Fix (Epidemiology); Graduated 2022
23. Sejin Lee (Health Policy); Graduated 2022
24. Bailey DeBarmore (Epidemiology); Graduated 2022
25. Jihye Park (Epidemiology); Graduated 2022
26. Henry Zhang (Epidemiology); Graduated 2022
27. Linnea Olssen (Epidemiology); Graduated 2023
28. Victoria Petermann (Nursing); Graduated 2023
29. Mostafa Mohamed (Epidemiology, University of Rochester); Graduated 2023
30. Molly Minnig (Epidemiology); May 2023-
31. Hui-Han Chen (Division of Pharmaceutical Outcomes and Policy); Graduated 2024
32. Natthawut (Max) Adulyanukosol (Biomedical and Health Informatics); January 2024-
33. Theo Beltran (Epidemiology); January 2024-

*INTERNATIONAL VISITING SCHOLARS*

1. Kathrine Lycke, BS  
Department of Clinical Epidemiology, Aarhus University, Denmark; Visit: Spring 2015  
Project title: Preadmission use of antidepressants and risk of complications and death after colorectal cancer surgery: A nationwide population-based cohort study
2. Anthony Matthews, MS, PhD  
London School of Hygiene and Tropical Medicine, England; Visit: Spring 2018  
Project title: Burden of cardiovascular disease among women age 66 and older diagnosed with non-metastatic breast cancer
3. Jakob Kirkegård, MD  
Department of Clinical Epidemiology, Aarhus University, Denmark; Visit: Spring 2018  
Project title: Acute and chronic pancreatitis and the risk of pancreatic cancer: a nationwide population-based cohort study
4. Blánaid Hicks, PhD  
Centre for Public Health, Queen's University, Belfast, Northern Ireland; Visit: Fall 2018  
Project title: Patterns of initiation and adherence to target therapies among older adults diagnosed with metastatic renal cell carcinoma

## **GRANT FUNDING**

### Pending

NCI (# pending) (Hubbard/Chubak) 07/01/2024-06/30/2028

**Targeting Time Zero: Tools for Bias Reduction in Real-World Data Analysis, total costs: \$2,147,003**

We will develop tools for evaluating bias of alternative design and analytic choices, accounting for challenges of secondary data, when applying the target trial framework. We will develop a framework, model, and software tools for assessing bias of alternative approaches to operationalizing eligibility, exposure, and covariate definitions when using EHR-derived data elements.

Role: Site Principal Investigator, 10% effort

### Current

ACS (# pending) (Reeder-Hayes) 01/01/2024-12/31/2028

**Geographic Small Area Estimation of Cancer Screening Rates: Precision Approaches to Inform Screening Equity, Outreach, and Interventions, total costs: \$1,200,000**

We will use insurance claims to measure and compare cancer screening use in small geographic areas and understand where racial disparities in screening are most prominent. We will then work with community partners to visualize these data and generate simulation models evaluating the potential effects of interventions to increase screening in certain geographic areas, for specific cancers and racial groups.

Role: Team Principal, 10% effort

FDA U01FD007937 (Sarsour) 09/01/2023-08/31/2024

**Development of novel methods to enable robust comparison of real-world Progression Free Survival (rwPFS) and Clinical Trial PFS in Multiple Myeloma**

This proposed study will generate critical evidence on how best to leverage real-world data and advanced statistical methods to accurately assess rwPFS in the setting of multiple myeloma. This project will focus on the development and application of bias correction methods for misclassification and surveillance bias.

Role: Project Collaborator, 17% effort

R01CA277756 (Lund/Henderson) 07/01/2023-06/30/2028  
**Applying causal inference methods to improve estimation of the real-world benefits and harms of lung cancer screening, total costs: \$1,764,414**

By leveraging data from a randomized controlled trial and multiple real-world data sources, the proposed study will evaluate the benefits and harms of lung cancer screening in clinical practice settings with a focus on optimizing internal and external validity by applying a novel causal inference methodology.  
Role: Multiple Principal Investigator (contact), 22% effort

NA (Lund) 07/01/2023-06/30/2024  
Gillings School of Global Public Health, Place and Health Grants  
**Building Infrastructure to Investigate Community Concerns about the Disparate Impacts of Extreme Weather-Related Disasters on Healthcare Access in North Carolina, total cost: \$30,000**

We propose to build and test the infrastructure needed to investigate high-priority, community-driven, research questions about the disparate impacts of extreme weather-related disasters on healthcare access in North Carolina. Through this infrastructure building, we will develop a geospatial data platform and assemble and establish a Community Advisory Board, establishing research procedures that allow for rapid analysis of community-driven concerns.  
Role: Principal Investigator (in-kind effort)

Westat, Contract #6473-S07 (Lund) 08/15/2019–08/14/2024  
**Constructing Real World Evidence in Cancer Surveillance Through Data Linkage and Advanced Methods: \$86,051**

To provide consulting and advisory services to the National Cancer Institute related to the uses and validity of real-world data for cancer research, related to novel linkages of cancer surveillance information to pharmacy dispensing and other related data.  
Role: Principal Investigator, 10%

R21 AG068965 (Lund) 05/01/2021-4/30/2024  
**Improving the prediction of life expectancy among older adults with advanced cancer using geriatric assessment, total costs: \$433,055**

This study will use detailed information from geriatric assessment and advanced statistical methods to develop and validate a new life expectancy prediction model for older adults (age 70 and over) with advanced cancer using geriatric assessment.  
Role: Principal Investigator, 20% effort

NIH/NIA, R01 AG056479 (Stürmer) 08/01/2022–07/31/2027  
**Propensity Scores and Preventive Drug Use in the Elderly**

Insights into and development of different novel analytic strategies to control for selection and confounding bias in non-experimental research based on propensity scores and validation data.  
Role: Co-Investigator, 10%

R01 CA237179 (Henderson) 08/01/2020-07/31/2024  
**National Cancer Institute, Comorbidity and Functional Status in a Population-Based Cohort of Patients Screened for Lung Cancer, total costs: \$ 2,194,547**

This study will evaluate whether risk-based lung cancer screening that incorporates pre-existing patient comorbid conditions and functional status can improve the delivery, quality, and outcomes of care in clinical practice.

Role: Co-Investigator, 10% effort

Past

PCORI ME2017C3-9337 (Lund) 03/01/2019-10/01/2023

**Patient-Centered Outcomes Research Institute, Enhancing hybrid study designs for comparative effectiveness research, total costs: \$856,230**

This study will develop research tools and guidance to improve the validity and encourage the use of hybrid study designs – drawing upon both randomized clinical trial and observational data - to update what is known about the benefits and harms of a new therapy when it is used in clinical practice settings.

Role: Principal Investigator, 35% effort

P30ES010126 (Troester) 03/01/2022-09/31/2023

**UNC Center for Environmental Health and Susceptibility, total costs: \$5,000**

Our funded pilot study will use the Research Prioritization by Affected Communities protocol as a guide to: (1) identify a diverse group of community stakeholders in Eastern NC most affected by hurricane-related flooding disasters, (2) design and lead facilitated discussions with this group about their concerns about these disasters and their impact on healthcare access, and (3) synthesize and prioritize community-identified research questions.

Role: Planning grant awardee (in-kind effort)

P30 AG066615 (Frankenberg/Aiello) 07/01/2020-06/30/2022

**National Institute on Aging, Carolina Center for Population Aging and Health, total costs: \$25,000**

Our funded pilot study will evaluate and compare the performance of contemporary screening tools to identify potentially inappropriate medications (PIMs) in older adults, document disparities in use by race/ethnicity, geography, and SES, and disentangle associations between longitudinal PIM use and important adverse health outcomes.

Role: Co-Principal Investigator, Pilot Grant (Lund/Yang), In-kind effort

FDA, BAA-19-00123-A3 (Jonsson Funk) 09/01/2019–08/31/2021

**Methodological Advances in the Assessment of Uncontrolled Confounding**

To develop and evaluate an array of sensitivity analyses used to assess the magnitude of uncontrolled confounding in observational studies.

Role: Co-Investigator, 10%

NIH/NIA R01 AG050733 (Trogdon) 09/01/2016-05/31/2020

**Cancer, Care Coordination, and Medication Use for Multiple Chronic Conditions, total costs: \$592,040**

This study will investigate patterns of care coordination and medication use for multiple chronic conditions among older cancer patients. It will identify gaps in care coordination and medication use during cancer treatment and in the transition to survivorship and highlight the effects of policies to improve care coordination.

Role: Co-Investigator, 10% effort

NA Lund (PI) 01/01/2018-06/30/2019

**Lineberger Comprehensive Cancer Center Developmental Grant: A multi-database approach to evaluating targeted therapy utilization, sequencing, and adherence in patients diagnosed with metastatic renal cell carcinoma (mRCC), total costs: \$50,000**

This study will investigate the real-world utilization, sequencing, and adherence to targeted therapies for mRCC by pooling information from large healthcare databases in the United States.

Role: Principal Investigator

R21 CA191454                      Lewis (PI)    01/01/2016-12/31/2018

**Improving Targeted Colorectal Cancer Screening in the Elderly, total costs: \$380,288**

This study uses North Carolina Medicare claims data to develop a prediction model to identify older adults who are unlikely to survive five or more years and are thus unlikely to benefit from colorectal cancer screening.

Role: Site Principal Investigator, 15% effort

NA                                      Lund (PI)    01/01/2018-12/31/2018

**IBM Junior Faculty Development Award: Investigating the effects of potential drug-chemotherapy interactions among older adults diagnosed with breast and colon cancer, total costs: \$10,000**

This study will evaluate the association between concomitant hydrochlorothiazide exposure and neutropenia-related hospitalizations in: (1) breast cancer patients initiating chemotherapy containing cyclophosphamide and (2) colon cancer patients initiating chemotherapy containing 5-fluorouracil.

Role: Principal Investigator

NA                                      Lund (PI)    01/01/2017-12/31/2017

**Lineberger Comprehensive Cancer Center Developmental Grant: Generalizing colorectal cancer trial results to real world populations: A pilot study, total costs: \$50,000**

This study will harness clinical trial, population-based cancer registry, and Medicare claims data to assess and apply model-based standardization for generalization of two colorectal cancer trials to target populations of patients treated in routine care. Our work in colorectal cancer will provide a framework for broader application to treatment trials from other cancer sites and generate preliminary data to support a R01-scale application to tailor the model-based standardization approach to enhance its relevance for the cancer trial setting.

Role: Principal Investigator

NIH/NCI K12                              Sharpless (PI)    07/01/2015-06/30/2017

**K12 Paul Calabresi Career Development Award for Clinical Oncology: Medication use, chemotherapy and adverse outcomes among older cancer patients, total direct costs: \$1,099,954**

This study will use the SEER-Medicare database to describe the prevalence and outcomes of polypharmacy, potentially inappropriate medication use and medications with the potential to interact with chemotherapy among older adults initiating chemotherapy for the treatment of non-metastatic breast, colon and lung cancer or non-Hodgkin lymphoma.

Role: Trainee, 75% effort

NA                                      Lund (PI)    07/01/2015-06/30/2017

**Data@Carolina Course Development Grant: EPID 766: Epidemiologic Research Using Healthcare Databases, total costs: \$10,000**

We will develop and incorporate two modules in this course that will provide students with: (1) an understanding of relational database concepts and design and how healthcare administrative utilization data can be normalized and transformed into common data models and (2) knowledge of currently available common data models.

Role: Principal Investigator



University of North Carolina at Chapel Hill, Department of Epidemiology Pharmacoepidemiology Faculty Search Committee Cancer Outcomes and Survivorship Faculty Search Committee	2020-2021
University of North Carolina at Chapel Hill, Department of Epidemiology PhD Admissions Committee, Member	2019-
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Protocol Review Committee, Member	2016-2019
University of North Carolina at Chapel Hill, Department of Epidemiology Departmental Chair Search Committee	2016-2017
University of North Carolina at Chapel Hill, Department of Epidemiology Graduate Studies Committee, Member	2014-2018
University of North Carolina at Chapel Hill International Society of Pharmacoepidemiology (ISPE), Student Chapter Co-Chair	2009-2010
University of North Carolina at Chapel Hill Student Global Health Committee, Education Committee Chair	2008-2009
<i>National and International</i>	
International Society of Geriatric Oncology Methods Working Group, Co-Chair	2023-
International Society of Pharmacoepidemiology Strategic Planning Committee	2022-
Fellow of the International Society for Pharmacoepidemiology (FISPE)	2021-
Board of Directors – Academic – Americas Representative	2021-
Real-World Evidence – Oncology Working Group, Core Group	2019-2022
Geriatric Pharmacoepidemiology Special Interest Group, Member	2018-
Education Committee, Member	2015-
Cancer Special Interest Group, Member	2013-
Comparative Effectiveness Research Special Interest Group, Member	2011-
Society of Epidemiological Research (SER) Poster Judge	2022, 2023
Awards Committee, Member	2018-2021
Education Committee, Member	2012-2016
Secretary, Student and Postdoc Committee	2009-2011
<i>Peer Review Committee – NIH, Foundations</i>	
UCSF – Program in Geriatric Oncology Pilot Grant Review Study Section	2022
National Cancer Institute / Office of Emergency Care Research	2021

Cancer and Emergency Medicine Research Small Group Forum

V Foundation, Review Committee 2020  
Robyn Roberts Thrivership Grants

National Cancer Institute, Special Emphasis Panel, Study Section Member, 2018  
Clinical & Translational Exploratory/Developmental Studies R21 and Omnibus R03

National Institute on Aging, Invited Reviewer 2018  
P01 Grant Application Reviewer

*Scientific Journal Editorial Board*

Epidemiology, Editorial Board Member 2022-  
Pharmacoepidemiology and Drug Safety, Core Concepts, Section Editor 2020-  
Pharmacoepidemiology and Drug Safety, Associate Editor 2019-  
Journal of Geriatric Oncology, Editorial Board Member 2018-

*Scientific Journal Peer Review*

American Journal of Epidemiology  
BMC Cancer  
Breast Cancer Research  
Cancer  
Cancer Causes and Control  
Cancer Epidemiology, Biomarkers, and Prevention  
Cancer Medicine  
CHEST  
Clinical Epidemiology  
Epidemiology  
eGEMs  
Gastroenterology  
Gut  
Health Services Research  
Inflammatory Bowel Diseases  
JAMA  
JAMA Network Open  
JAMA Oncology  
Journal of the American Geriatrics Society  
Journal of Cancer Research and Clinical Oncology  
Journal of Clinical Epidemiology  
Journal of Geriatric Oncology  
Journal of the National Cancer Institute  
Medical Care  
Obesity  
Pharmacoepidemiology and Drug Safety  
The Oncologist